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Cell Polyomavirus Life Cycle
Abstract
Due to its association with Merkel cell carcinoma (MCC), a substantial effort has been made to better
understand how Merkel cell polyomavirus (MCPyV) proteins drive oncogenesis; however, our
understanding of the early steps of MCPyV infection remains poor. The polyomavirus Large Tumor
antigen (LT) is a highly multi-functional protein with a wide range of activities, including: stimulation of
cellular proliferation through its interaction with retinoblastoma protein and DnaJ heatshock protein
family members; arrest of the cell cycle through a poorly understood activity localized to the C-terminal
region; and regulation of the initiation of viral DNA replication. LT proteins also play important roles in
regulating viral transcription. How these various functions are regulated to ensure an orderly progression
of events conducive for the viral life cycle has not been well established.
In this study, I show how phosphorylation of MCPyV LT plays an important role in regulating its many
functions. I identify threonines 297 and 299 as key phospho-sites which regulate LT's ability to initiate
replication. T297 phosphorylation inhibits LT binding to the viral origin of replication and acts as an "off"
switch, while phosphorylation of T299 is required to stimulate LT-mediated replication of viral genomes.
This study was the first to identify phosphorylation sites of LT and link them to important protein
functions.
Cross-reactivity to a phospho-specific antibody revealed yet another phosphorylation site on MCPyV LT as
S816. We discovered that this phosphorylation event is mediated by ATM kinase, and may play a role in
the MCPyV LT C-terminal domain's ability to arrest the cell cycle. This study helps to further elucidate
MCPyV's association with the host DNA Damage Response (DDR) and provides some rational for the
recruitment of these factors to viral replication centers.
Finally, studies of the viral non-coding control region (NCCR) reveal a surprising interaction between LT
and sT on the late promoter. MCPyV LT is able to robustly stimulate the late promoter only in the context
of an intact Ori and sT co-expression. Using phosphomutant LTs and mutant Ori sequences, I highlight the
importance of LT binding to the Ori and stimulation of replication as key factors in LT-mediated activation
of the late promoter in the context of sT co-expression. LT alone actually represses the late promoter and
requires sT coexpression to efficiently stimulate the late promoter after replication. This study therefore
reveals an important dependence on sT expression for the regulation of transcription that has not yet
been reported with other polyomaviruses.
In sum, this study demonstrates multiple mechanisms of regulation including protein phosphorylation,
protein-DNA interactions, and co-expression of key viral proteins as regulators of LT function. These
studies may help elucidate critical factors required for establishing a robust cellular infection system
which is greatly needed to further our understanding of the basic virology of this important human tumor
virus.
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ABSTRACT

NOVEL REGULATORY MECHANISMS BY WHICH LARGE T ANTIGEN
COORDINATES THE MERKEL CELL POLYOMAVIRUS LIFE CYCLE
Jason Diaz
Dr. Jianxin You
Due to its association with Merkel cell carcinoma (MCC), a substantial effort has
been made to better understand how Merkel cell polyomavirus (MCPyV) proteins drive
oncogenesis; however, our understanding of the early steps of MCPyV infection remains
poor. The polyomavirus Large Tumor antigen (LT) is a highly multi-functional protein
with a wide range of activities, including: stimulation of cellular proliferation through its
interaction with retinoblastoma protein and DnaJ heatshock protein family members;
arrest of the cell cycle through a poorly understood activity localized to the C-terminal
region; and regulation of the initiation of viral DNA replication. LT proteins also play
important roles in regulating viral transcription. How these various functions are
regulated to ensure an orderly progression of events conducive for the viral life cycle has
not been well established.
In this study, I show how phosphorylation of MCPyV LT plays an important role
in regulating its many functions. I identify threonines 297 and 299 as key phospho-sites
which regulate LT’s ability to initiate replication. T297 phosphorylation inhibits LT
binding to the viral origin of replication and acts as an “off” switch, while
phosphorylation of T299 is required to stimulate LT-mediated replication of viral
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genomes. This study was the first to identify phosphorylation sites of LT and link them
to important protein functions.
Cross-reactivity to a phospho-specific antibody revealed yet another
phosphorylation site on MCPyV LT as S816. We discovered that this phosphorylation
event is mediated by ATM kinase, and may play a role in the MCPyV LT C-terminal
domain’s ability to arrest the cell cycle. This study helps to further elucidate MCPyV’s
association with the host DNA Damage Response (DDR) and provides some rational for
the recruitment of these factors to viral replication centers.
Finally, studies of the viral non-coding control region (NCCR) reveal a surprising
interaction between LT and sT on the late promoter. MCPyV LT is able to robustly
stimulate the late promoter only in the context of an intact Ori and sT co-expression.
Using phosphomutant LTs and mutant Ori sequences, I highlight the importance of LT
binding to the Ori and stimulation of replication as key factors in LT-mediated activation
of the late promoter in the context of sT co-expression. LT alone actually represses the
late promoter and requires sT coexpression to efficiently stimulate the late promoter after
replication. This study therefore reveals an important dependence on sT expression for
the regulation of transcription that has not yet been reported with other polyomaviruses.
In sum, this study demonstrates multiple mechanisms of regulation including
protein phosphorylation, protein-DNA interactions, and co-expression of key viral
proteins as regulators of LT function. These studies may help elucidate critical factors
required for establishing a robust cellular infection system which is greatly needed to
further our understanding of the basic virology of this important human tumor virus.
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CHAPTER 1: INTRODUCTION

1.1: Merkel Cell Carcinoma and Merkel Cell Polyomavirus
1.1.1 Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) was first described in 1971 by Cyril Toker as a
trabecular tumor of the dermis (1). MCC is thought to arise from Merkel cells, a unique
cell type of the skin, which transmit fine-touch sensation and have characteristics of both
epithelial and neurosecretory cells (2). MCC was long regarded to be a rare cancer, with
an incidence of around 2 cases per million in 1984, but this rate has tripled over
subsequent decades. Old age, immune suppression, and UV exposure are the major risk
factors for MCC disease (3,4). Although rare, MCC is a very aggressive cancer, with a
mortality rate as high as 30% (5).

Risk of MCC increases dramatically at older ages, and is also increased with
immunosuppression (4). These factors led Chang and Moore to investigate whether
MCC was associated with an infectious agent. Using Digital Transcriptome Subtraction,
they identified a unique transcript expressed at extremely high levels in these tumors,
which did not match known human transcripts; sequence analysis showed that it was
homologous to the major viral protein of polyomaviruses, the Large Tumor (LT) antigen.
Using PCR and sequencing techniques, they were then able to identify a novel
polyomavirus clonally integrated within the genomes of the four tumor samples they
analyzed. They named this new polyomavirus Merkel cell Polyomavirus (MCPyV) for
its association with MCC (6). Subsequent analysis of MCC tumors have shown that
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MCPyV sequences can be found in at least 80% of all MCC cases examined, although
more recent advances in detection methods has shown an association as high as 97% (7).
MCPyV is the first human polyomavirus that has been associated with a human cancer
and has generated a lot of interest in the tumor virology field.

1.1.2 Merkel Cell Polyomavirus and Cancer
Polyomavirus associated cancers are generally driven by the expression of LT (8).
The N-terminal half of LT can bind to many cellular proteins, including DnaJ family
members and pRb, to drive host cell proliferation.

The C-terminal half of LT is

important for initiating replication from the viral origin, and includes an origin binding
domain (OBD) and a helicase domain. Interestingly, LT was found to be expressed in a
truncated form in almost every MCPyV-associated MCC tumor analyzed (9). While the
truncations were unique to every tumor, they universally deleted the C-terminal half of
the protein required for viral replication while retaining the N-terminal half, which could
still inhibit key tumor suppressors like pRb. This led Chang and Moore to initially
hypothesize that viral replication of the integrated MCPyV genome was antithetical to
tumor progression, a theme shared with papillomavirus associated cancers. In support of
this hypothesis, they described a unique MCC tumor that retained wild-type expression of
LT, but had a mutated origin of replication (Ori350), rendering the integrated sequence
replication incompetent (9,10).

These observations bear a striking resemblance to

papillomavirus associated cancers, where deletion of the major regulatory protein E2
decreases replication from the viral origin and induces overexpression of the viral
oncogenes (11,12). Since that initial hypothesis, further study of the C-terminal domain
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has also revealed a growth-inhibitory property linked to the activation of a host cell DNA
Damage Response (DDR), and it has been hypothesized that this region of LT is
therefore negatively selected during oncogenesis (13,14).

Since its discovery in 2008, many reagents and tools have been developed to
study MCPyV prevalence. Generation of a monoclonal antibody against MCPyV LT
allowed investigators to screen MCC tumors for presence of the viral antigen, while
production of viral particles allowed studies of viral infection to be performed in cell
culture and provided a capture method for screening human sera for antibodies against
MCPyV (15-20). Serological studies indicate that MCPyV seroconversion occurs early
in childhood and that most adult individuals harbor antibodies against MCPyV
(16,18,19).

In agreement with this finding, Rolling Circle Amplification and deep

sequencing of DNA obtained from skin tissue gave evidence of chronic shedding of
MCPyV in healthy human donors (21,22). These observations suggest that MCPyV
establishes an early, persistent, subclinical infection, and that a rare few individuals go on
to develop MCPyV related cancer.

Given its early and ubiquitous infection in human skin, it is vital to understand
basic MCPyV virology and how viral infection leads to cancer. Extensive study of the
prototypical polyomavirus, Simian Virus 40 (SV40) has given the field a strong
foundation for understanding MCPyV associated oncogenesis, but this framework has
only taken us so far.

Many key differences unique to MCPyV have already been

described. Phylogenetically, MCPyV is more closely grouped with murine polyoma
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virus instead of SV40; this is in contrast to the better described human polyomaviruses
JK and BC virus (6,8,23). Additionally, MCPyV LT bears two important differences
from its SV40 counterpart. The first is the existence of an N-terminal 200 amino acid
stretch of peptide flanking the pRb binding site not found in any other polyomavirus LT;
this region has been termed the MCPyV Unique Region (MUR) (24,25). The second
major difference is that MCPyV LT does not appear to bind the key tumor suppressor
p53 (or binds with extremely low affinity), a finding that challenges conventional
understanding of polyomavirus-associated oncogenesis (26). MCPyV sT also appears to
act differently than its SV40 homologue: MCPyV sT plays a much more dominant role in
tumorigenesis, and interacts with its key cellular target, PP2A phosphatases, in ways
distinct from SV40 sT (27). Finally, the non-coding control region (NCCR) of the viral
genome, which bisects the circular genome into an early and late region, is organized
more similarly to mouse polyomavirus genome architecture than the more extensively
studied SV40 NCCR (10,28).

Regulation of both gene expression and replication

through the NCCR may be different for MCPyV than SV40; indeed, recruitment and
assembly of the origin binding domains of MCPyV LT around the viral origin has already
been shown to be unique (28).

The focus of my work has been to further our

understanding of how MCPyV LT’s multiple functions are regulated through posttranslational modifications. I have also sought to better elucidate how viral transcription
from both the early and late promoters is regulated, which will both shed new light on
MCPyV persistent infection and might also explain how expression of viral oncogenes
during tumorigenesis is regulated.
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1.2 Merkel Cell Polyomavirus Virology
1.2.1 MCPyV Genes and Genome Organization

Figure 1.1 Organization of the MCPyV genome. The genome is bisected into two regions by a central
non-coding control region (NCCR) which contains the promoters for the early and late genes, as well as
the viral Origin of Replication (Ori). The Tumor Antigen is expressed early in infection, and is multiply
spliced into many proteins, including Large T antigen (LT), small T antigen (sT), antigen of 57 kDa
(57kT), and Alternate frame of the Large T Open reading frame (ALTO). The capsid proteins VP1 and
VP2 are expressed following genome replication.
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MCPyV is a double-stranded DNA virus with a circular genome of about 5.3kb
protected by an icosohedral capsid. The genome is divided into two regions by an NCCR
housing the origin of replication (Ori) and promoter sequences (Figure 1.1). The early
and late regions flank this NCCR in opposite directions.

The Tumor-antigen open

reading frame is expressed from the early promoter and multiply spliced into mRNAs
expressing four products: Large T antigen (LT), small T antigen (sT), 57kDa T antigen
(57kT), and Alternate frame of the Large T Open reading frame (ALTO).

These

nonstructural genes primarily manipulate the host cell and are also responsible for
replication of the viral genome. From the late promoter, two capsid proteins (VP1 and
VP2) are expressed which package viral genomes into nascent virions. Of these viral
proteins, both MCPyV LT and sT proteins have been found expressed in MCPyV related
tumors and have therefore been the most extensively studied thus far (6,8,23).

1.2.2 Large T Antigen
Like other polyomavirus LT proteins, MCPyV LT can bind pRb and DnaJ family
members, which drives host cell proliferation; the domains responsible for these
functions generally remain intact in virus-associated MCC as well, and are likely a
driving force for proliferation of these tumors (9). Classically, polyomavirus LTs bind
and inhibit the tumor suppressor p53; the dual inhibition of pRb and p53 is a common
feature of oncogenic DNA viruses like papillomaviruses and certain herpesviruses (29).
Association of p53 with MCPyV LT has only recently been reported, but this interaction
was weak and concluded to be indirect (26); additionally, the p53 binding domains of
SV40 LT lie within the helicase domain, which in most MCPyV associated tumors is
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deleted from LT due to nonsense mutations in the LT gene (9). MCPyV may be unique
among polyomaviruses for lacking a direct interaction with p53; in fact, LT expression
may actually activate p53 downstream signaling indirectly through activation of the host
DDR (14). Further investigation is required to better understand MCPyV’s relationship
with this key tumor suppressor.

MCPyV LT encodes a 200 amino acid stretch flanking the LXCXE pRb binding
motif which is not found in any other polyomavirus LT. The function of this MUR
remains largely unknown. A host protein involved in the fusion of lysosomes, Vam6p,
was identified as a LT binding partner in cells which associated with the MUR, but the
functional relevance of this interaction in relation to the viral life cycle has not been
elucidated (24). Finally, like other polyomaviruses, MCPyV LT is necessary and
sufficient for the initiation of replication from the viral Ori in the NCCR (10), which will
be reviewed in depth below (1.3) and will be the focus of the work presented in Chapter
2.

In SV40, LT is necessary and sufficient for transforming cells in culture, while sT
plays a lesser role in transformation (30,31). In contrast, expression of MCPyV LT alone
is not sufficient to transform any cells studied thus far. In fact, expression of wild type
LT commonly leads to growth arrest, a feature that has been localized to an activity
intrinsic to the C-terminal domain, which is commonly deleted in MCPyV associated
tumors (13,14). This growth arresting activity requires wild type p53 activity and a host
DNA damage response instigated by the C-terminal portion of LT, and likely explains
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why MCPyV LT has poor transformation activity when expressed alone (14). Truncated
LT’s with this inhibitory activity deleted may still play an important role in
tumorigenesis, however, as mouse xenograph transplant experiments have demonstrated
a requirement for tumor-derived LT in MCPyV associated MCC tumors (32).

1.2.3 MCPyV Small T Antigen
MCPyV sT has emerged as a key player in MCPyV associated oncogenesis.
Early studies of sT confirmed that its expression can transform rat cells, and it is
commonly expressed in many MCPyV associated tumors (27,33,34).

Like other

polyomaviruses, MCPyV sT shares its N-terminal DnaJ domain with LT, while its Cterminal half encodes a PP2A phosphatase binding domain. SV40 sT’s contribution to
oncogenesis has been linked to its ability to bind and inhibit PP2A phosphatases, thereby
preventing the dephosphorylation of Akt, rendering it constitutively active (35-37).
MCPyV sT, in contrast, acts further downstream of Akt, and is able to induce
hyperphosphorylation of 4E-BP1, thereby releasing eIF4E to stimulate cap-dependent
translation, independently of PP2A binding (27). The PP2A binding domain of MCPyV
sT is not dispensable, however; this domain allows it to bind the adaptor protein NEMO,
possibly in complex with certain PP2A or PP4A subunits, to disrupt host cell
inflammatory signaling mediated by NF-κB (38).

Additionally, PP2A binding by

MCPyV sT was shown to destabilize microtubules by disregulating phosphorylation of
stathmin, a key microtubule binding protein (39). This destabilization led to increased
cell migration and invasion, and may explain why MCC tumors are prone to rapid
metastases (39).
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MCPyV sT has also been shown to stabilize the expression of MCPyV LT
through its inhibition of the E3 ubiquitin ligase SCFFbw7 (40). This stabilization of LT is
unique to MCPyV, as other sT proteins generally don’t affect the protein levels of their
cognate LT proteins. LT-mediated replication of viral origins is greatly enhanced when
sT is also expressed, once again highlighting sT’s more prominent role in MCPyV
(10,40).

1.2.4 Additional Early Gene Products
The other two viral proteins, 57kT and ALTO, are much less understood. 57kT is
an alternatively spliced T-antigen of 432 amino acids (9,41). It shares the first 332 amino
acids of LT, including the DnaJ and pRb binding sites, the MUR and a nuclear
localization signal, but lacks LT’s origin binding domain and the majority of the helicase
domain. It similarly shares its C-terminal 100 amino acids with LT. Robust expression
of 57kT appears to require viral replication but its function remains unknown. It is
sometimes compared to SV40’s 17kT, a small protein which similarly shares sequences
with its cognate LT, and which appears to behave both independently and in concert with
other T-antigens to control cellular proliferation (42,43). Given that 57kT retains both
tumor suppressor (DnaJ, pRb) binding domains and the C-terminal region of LT shown to
inhibit growth, it will be interesting to study this protein’s role in cell cycle manipulation
and investigate what role(s) it plays during natural infection.

The overprinting gene, ALTO was discovered as a cryptic reading frame within
the T-antigen locus that is evolutionarily related to the murine polyomavirus middle T
	
  

9	
  

antigen (44). Its expression can be detected in cells carrying MCPyV molecular clones
but its role during infection remains to be elucidated (44).

1.2.5 MCPyV Late Genes
The late region of MCPyV encodes two capsid proteins, VP1 and VP2. A third
capsid gene, VP3, is predicted by sequence analysis but has never been shown to be
expressed; indeed, attempts to express this capsid have failed (17). These proteins are
expressed after replication and encapsidate newly replicated viral genomes into nascent
virions. The major capsid protein, VP1, is necessary and sufficient for the production of
psuedovirions. VP2 is a minor capsid protein which is required for efficient infection of
a number of cell lines, although its precise mechanism of action remains to be fully
explored (19,41,45,46). Initial reports identified sialic acid as the major attachment
factor for MCPyV, similar to other polyomaviruses (47).

Subsequent studies have

uncovered a more nuanced process where binding to sulfated glycosaminoglycans,
especially heparin sulfate, was required in addition to sialic acid for efficient entry (46).
The crystal structure of VP1 confirmed a sialic acid binding pocket, but mutation of this
domain did not inhibit initial attachment of virions to target cells, supporting a model
where heparin sulfate acts as an initial attachment factor with subsequent binding of sialic
acid required for internalization into the target cell (48). This dual-receptor paradigm is
novel among polyomaviruses, once again highlighting MCPyV’s novelty.

	
  

10	
  

1.2.6 Natural Infection of MCPyV
Thus far the natural host cell of MCPyV has not yet been identified. Merkel cells
are post-mitotic and do not support robust infection of MCPyV, and are thought to be a
dead-end host cell. The lack of a robust in vitro system for propagating the virus has
hampered our ability to thoroughly study MCPyV’s life cycle, so research efforts have
thus far studied various aspects of the virus life cycle in isolation.

For example,

psuedovirions composed of the viral capsids encapsidating either an MCPyV molecular
clone or a reporter construct have been useful in better understanding viral entry (46-48).
Similarly, ectopic expression of viral proteins alone or in combination allowed for the
discovery of many of the functions described for LT and sT in sections 1.2.2 and 1.2.3
above. Additionally, identification of cell lines that support replication of the viral Ori
have allowed for an in-depth exploration of this key step of the viral life cycle
(10,17,41,49,50).

To date, a significant portion of MCPyV research has focused on the oncogenic
properties of both LT and sT. Regulation of key processes such as genome replication
and transcription remains to be thoroughly explored. A better understanding of how
these early events are regulated during natural infection can provide clues for
understanding how these processes might then be altered during oncogenesis, and may
even point to therapeutic targets in MCPyV associated tumors.
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1.3 Polyomavirus Genome Replication
1.3.1 LT-mediated Initiation of Replication
SV40 replication has been an essential model for understanding eukaryotic
replication (51). This section will review the formation of the polyomavirus replication
initiation complex, directed by LT, followed by mechanisms of regulation in section
1.3.2. A discussion of our current understanding of MCPyV replication will be the focus
of section 1.3.3.

Figure 1.2 Organization of polyomavirus origins of replication. Pentanucleotide sequences (GAGGC)
which are recognized by LT are denoted with a “P” and highlighted in blue, while inverted complimentary
binding sites (CTCCG) are highlighted in magenta. Arrows denote the orientation of bound LT. The A/T
rich tract (A/T) and Early Palindrome (EP) are also indicated. Py – murine polyomavirus. Adapted from
Harrison et al., 2011 (28).

The SV40 Ori is located at the center of the NCCR, and is flanked on both ends
by the early and late promoters. The Ori is comprised of three functional domains (see
Figure 1.2, bottom). The central domain, Site II, contains four GAGGC pentanucleotide
repeats which serve as LT binding sites. Site II is flanked on the early side by the Early
Palindrome (EP) and on the late side by an A/T rich tract (A/T), both of which are easily
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melted and serve as the initial sites of unwinding and recruitment of the DNA replication
machinery (51).

SV40 LT binds the viral origin and forms hexameric complexes to initiate
replication. LT contains two domains critical for replication: an OBD and a helicase
domain. The OBD specifically recognizes the GAGGC pentanucleotide repeats of Site
II, and additionally make contacts with the other OBD of adjacent LT molecules during
hexamer formation (52,53). The helicase domain makes non-specific interactions with
DNA, especially single stranded DNA, and helps stabilize LT recruitment to the Ori. The
helicase domain also contains an ATPase domain required for unwinding activity; this
activity can be stimulated by single stranded DNA (54-56). In addition to forming a viral
helicase required for unwinding of the genome, LT recruits key cellular replication
factors including RPA70, RFC1 and DNA Polymerases to the viral origin (51,57).

LT is the only viral protein required for initiating replication of the genome.
Biochemical analysis of a variety of LT mutants, as well as extensive structural analyses,
have allowed for a deep understanding of the initial events of replication initiation, which
will be briefly summarized. The OBD recruits LT specifically to the viral Ori, where the
arrangement of the GAGGC pentanucleotides causes a head-to-head configuration of LT
molecules (53). These LT proteins then recruit additional LT molecules to form two
hexameric complexes at the Ori (58). During hexamer formation, the OBDs release the
Ori DNA and form contacts with each other to stabilize the hexamer, while the nonspecific DNA interactions from the helicase domains keep the complexes localized to the
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viral genome (53). The ATPase activity of the helicase domains are then activated and
the hexameric complexes begin unwinding the viral genome at the A/T and EP domains
flanking Site II. After initial unwinding of the DNA, the LT helicase continues to
unwind the genome as the cellular replication machinery, recruited by LT, begins
replicating the viral genome. In vitro replication studies have shown that magnesium and
ATP are required to stimulate helicase activity, while initial hexamer formation of LT
requires ATP binding but not hydrolysis, as non-hydrolizable analogues can still
stimulate hexamer formation (53,58-70).

1.3.2 Regulation of Viral Replication
In addition to orchestrating replication of the viral genome, LT has many other
important functions which are required for manipulating the host cell to drive
proliferation, as has been outlined above. Initiation of replication must be timed to occur
when the host cell is most permissive to replication.

This switch is mediated by

phosphorylation of LT at threonine 124 (T124) (71,72). Phosphorylation at T124 is
required for LT to be replication competent, and is thought to stimulate interactions
between both hexamers at the Ori which lead to initiation of unwinding (73). Cyclin
dependent kinases have been shown to phosphorylate LT at this site in vitro, but have not
been definitively proven to perform this function in vivo (71). In addition to T124,
phosphorylation at serines 120 and 123 plays an indirect role in regulating replication.
Specifically, S120/123 phosphorylation is required for efficient nuclear import of LT but
diminishes LT’s ability to initiate replication. These phosphorylation marks must be
removed prior to replication, likely by PP2A phosphatases. The kinase(s) responsible for
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phosphorylating S120/123 remains to be confirmed, but these phosphorylation events can
be simulated in vitro with casein kinase (74-79).

Many DNA viruses have been shown to manipulate the host DDR for their
replication. SV40 has been shown to recruit DDR factors to viral replication foci (80).
Additionally, ATM kinase, a key regulator of double-strand break repair, has been shown
to phosphorylate LT directly, and this activity was required for replication (81). While
the interaction between SV40 and the host DDR has been well documented, the
functional/mechanistic role(s) of these DDR proteins still requires exploration.

1.3.3 MCPyV Genome Replication
MCPyV genome replication follows the SV40 model to a large extent. MCPyV
LT is the only protein required for initiating replication, although co-expression of sT can
boost LT’s activity by stabilizing LT protein expression (10). MCPyV LT recognizes the
viral Ori through its OBD; neither SV40 nor MCPyV LT can recognize the other’s Ori at
a level that allows for replication (28). Interestingly, the MCPyV Ori is organized more
similarly to the murine polyomavirus Ori (Figure 1.2, top): it lacks a true early
palindrome region and instead has two A/T tracts that flank the central pentanucleotides.
Additionally, instead of having a symmetrical set of four GAGGC pentanucleotides at the
center of the Ori, MCPyV contains ten GAGGC repeats within the NCCR, eight of which
are relevant to replication; LT binds four of these repeats in an asymmetric fashion (P1,
P2, P4 and P7) which has been shown to be similar to murine polyomavirus LT’s origin
binding architecture (10,28,82). Notably, crystal structures predict that MCPyV LT
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OBDs make more extensive contacts with each other on the viral origin compared to
SV40 LT (28). Novel to MCPyV replication is LT’s ability to recruit the host protein
Brd4 to replication foci, which in turn recruits Replication Factor C; this activity was not
seen with SV40 LT, but has been shown to be relevant to papillomavirus replication
(50,83). Similar to SV40, however, is the recruitment of host DDR proteins to actively
replicating MCPyV viral genomes (49). The recruitment of these proteins appears to be
necessary for efficient replication of the viral genomes in cells, although the detailed
mechanisms by which these DDR proteins assist replication remain to be elucidated (49).
Recruitment and manipulation of the host DDR has emerged as a common theme among
DNA viruses, and MCPyV LT expression alone can elicit a robust DDR in cells, even in
the absence of viral genomes (14).

Important questions remain for MCPyV replication. The role(s) played by DDR
proteins at replication foci remains to be elucidated. Additionally, contribution from sT
beyond its stabilization of LT has yet to be explored in the context of replication. Finally,
whether MCPyV LT is phosphorylated as a means of controlling the replication process
has not yet been described.

1.4 Regulation of Polyomavirus Transcription
1.4.1 SV40 Gene Regulation
Regulation of both early and late promoters for SV40 has been well described.
The early promoter contains binding sites for many cellular transcription factors,
including Sp1, Sp2, AP-1, AP-4 and NFAT (84-87).
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A TATA box targets the

transcription machinery to the correct start site (88). As expression of LT increases
during early infection, the early promoter becomes inactivated. During and especially
after LT has initiated replication of viral genomes, the early promoter is shut down while
the late promoter is activated to express the capsid proteins (87). LT directly mediates
the repression of the early promoter and activation of the late promoter; sT’s involvement
in either event has not been well established, although one report shows that sT can help
compliment the activity of a sub-optimal level of LT expression (89).

1.4.2 MCPyV Gene Regulation
Regulation of MCPyV transcription has thus far not been studied. Only a few cell
lines support expression of viral proteins from their natural promoters, and the few
reports on the topic are largely observational. Expression of viral proteins from native
MCPyV genomes is highly restricted in all cell lines tested thus far (14,41,45,46,49,90);
the mechanism(s) regulating viral MCPyV transcription remains unexplored. A better
understanding of how the viral promoters, especially the early promoter, are regulated is
vital for understanding viral oncogene expression in MCPyV associated cancers as well
as in naturally infected cells.

1.5 Scope of My Work
My work has focused on early events of MCPyV infection, including replication
and transcription, and has also explored how post-translational modifications regulate LT
function. In Chapter 2, I identify three novel phosphorylation sites on MCPyV LT and
go on to describe how they regulate LT-mediated replication of viral genomes. In
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Chapter 3, I identify a fourth phosphorylation site on the extreme C-terminus of LT and
demonstrate how this phosphorylation event, mediated by ATM kinase, may contribute to
the growth-inhibitory properties of the C-terminal region of LT. Finally, in Chapter 4 I
offer a preliminary analysis of MCPyV transcription from both early and late promoters.
I describe how replication is tied to transcriptional activation and demonstrate a unique
dependence of LT on sT co-expression for upregulation of the viral late promoter.
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CHAPTER 2: PHOSPHORYLATION OF LARGE T ANTIGEN REGULATES
MERKEL CELL POLYOMAVIRUS REPLICATION	
  

I was the principal investigator who designed and performed the experiments in
this chapter, and prepared the associated manuscript published in Cancers. Jing Jiao
prepared the LT sample for mass spectrometry analysis, which was performed by the
School of Medicine Proteomics Core (Figure 2.1A), while I performed the protein
alignment (Figure 2.1B). Dr. Jianxin You assisted in modeling the extended OBD of LT
in contact with DNA (Figure 2.2). Sabrina Tsang assisted in performing the replication
assay in Figure 2.5. Dr. Xin Wang was of great assistance in performing the in vitro
biochemical assays to probe the LT phosphomutants for their ability to bind and unwind
the viral origin (EMSA in Figure 2.6, Unwinding Assay and Helicase assays in Figure 2.7
and 2.8).

This research was originally published in Cancers. Jason Diaz, Xin Wang, Sabrina H.
Tsang, Jing Jiao, and Jianxin You. Phosphorylation of Large T Antigen Regulates
Merkel Cell Polyomavirus Replication. Cancers (2014) 6(3): 1468-86
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2.1: CHAPTER SUMMARY
Polyomavirus Large T antigen (LT) is a multifunctional protein which
manipulates the host cell and regulates replication of the viral genome as well as
transcription of both the early and late promoters. These multiple functions must be
closely regulated to ensure each step of the viral life cycle is executed correctly.
Phosphorylation is a major regulator of protein function, but no studies have yet been
performed for MCPyV LT. Using mass spectrometry, I identified three phosphorylation
sites in MCPyV LT: T271, T297 and T299. T299 is homologous to a highly conserved
threonine found in all the major polyomavirus LTs I examined; phosphorylation of the
homologous threonine in SV40 LT stimulates its ability to initiate viral replication. Using
the tools already developed in our lab for studying MCPyV replication, I showed by
immunoflourescene and southern blotting that alanine mutants of MCPyV LT T297 and
T299 dramatically affected viral replication without affecting recruitment of replication
factors: T297A stimulated replication well over levels seen by wild-type LT, while
T299A was replication defective, as was predicted by homology to SV40 LT. Further
biochemical analyses showed that th MCPyV LT T297A mutant could bind the origin of
replication with increased affinity, while the T299A mutant had reduced binding,
compared to wild-type. The unwinding and helicase activities of LT was unaffected by
these mutations. These results showed that phosphorylation at two sites in MCPyV LT
dramatically regulates its ability to replicate, and identified a third, novel site at T271 in a
unique region of MCPyV LT that warrants further investigation.
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2.2: INTRODUCTION
MCPyV is the first human polyomavirus to be linked to a human cancer MCC
(3,6,8). Since its discovery in 2008, this virus has been found clonally integrated in a
majority of MCC tumors. In most MCPyV related MCC tumors the major viral protein,
LT, has been mutated such that it is expressed in truncated forms (9). These tumorderived truncated LT proteins retain their binding sites for pRb and DnaJ family
heatshock proteins, thereby driving proliferation (3,9). Indeed, at least one study has
shown that tumors with knocked-down LT protein regress rapidly in a xenograft model
(32). Both LT and the splice variant sT have been shown to have oncogenic properties
(10,32,33,91), although the precise contribution of each protein to the process of
tumorigenesis is still unclear.

MCPyV appears to be a natural resident of the skin microflora, and is acquired
early in life (19,21,22). While considerable efforts have been made to better understand
MCPyV’s oncogenic potential, especially in MCC tumors, comparatively little work has
been done to better understand this virus’s basic life cycle. The lack of a relevant cell
culture system for propagating virus has made investigations of its basic virology
difficult; however, ectopic expression of MCPyV LT in cell lines such as HEK 293,
C33A and U2OS has been valuable in enhancing our understanding of MCPyV’s
interaction with host cells (14,41,50,92).
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Our lab has previously characterized MCPyV LT’s interaction with the host cell
to stimulate replication (50). In that study we showed by immunoflourescent staining
(IF), fluorescent in situ hybridization (FISH) and BrdU staining that MCPyV LT proteins
form large nuclear foci which contain actively replicating plasmids carrying the viral Ori.
We also showed that several cellular factors colocalize to these foci, including: the
double bromodomain protein, Brd4, the PCNA loading protein replication factor 1
(RFC1), and the single-stranded DNA binding protein RPA70. In another study we
demonstrated that full length MCPyV LT activates host DNA damage response (DDR)
pathways and dramatically alters the host cell cycle (14). Additionally, members of the
DDR pathway were seen to colocalize with nuclear foci containing actively replicating
viral genomes, potentially contributing to viral replication (49). While it is still unclear
whether DDR activation and recruitment upon LT expression is a side-effect of active
viral replication and/or LT helicase activity, or if this activation is being actively
subverted and manipulated by MCPyV, the link between MCPyV LT expression and
DDR activation is well established. This DDR activity, coupled with LT’s ability to
dramatically alter the host cell cycle, may provide enough low-level genomic instability
to lead to integration of the MCPyV genome into the host cell genome, which appears to
occur in the majority of MCPyV-related MCC tumors (7).

Merkel cells may not represent the natural host cell of MCPyV and may predispose MCPyV to randomly integrate its genome.

Indeed, the prototypical

polyomavirus SV40 has a transforming phenotype in cell lines that are non-permissive
for viral replication (30); Merkel cells may similarly represent a non-permissive host for
	
  

22	
  

MCPyV. A better understanding of how MCPyV replication is regulated would provide
a clearer framework for understanding how infection may be altered in Merkel cells and
lead to integration of the mutated viral genome.

SV40 LT has been a model for understanding eukaryotic replication for decades
(51). SV40 LT is recruited to the viral Ori through its OBD, which recognizes GAGGC
pentanucleotide repeats arranged symmetrically within the Ori. LT then oligomerizes
into two hexameric protein complexes arranged in a head-to-head fashion. The Cterminal helicase domains make non-specific contacts with an extended palindrome and
an A/T rich tract flanking the central pentanucleotide repeats; these become the initial
sites of unwinding. SV40 LT then acts as a helicase to unwind the viral genome and
recruits cellular factors to begin replication (51,57).

Phosphorylation has been a well established mechanism by which SV40 LT
replication is regulated (93). T124 was identified as a critical residue for regulating
SV40 LT-mediated viral replication; removal of this phosphorylation either
biochemically or genetically abrogated replication (71,94-96). Intensive biochemical
studies demonstrated that this phosphorylation plays an important role in mediating
interactions between both hexamers at the Ori. Alanine mutants are defective in forming
double-hexamer complexes and unwinding the viral origin (68,73).

Somewhat paradoxically, early biochemical analyses of purified SV40 LT seemed
to indicate that phosphatase treatment could actually stimulate viral replication in vitro
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(75,78). It was later clarified that, in addition to phosphorylation at T124, there are serine
phosphorylation modifications nearby which have an inhibitory effect on viral replication
(74).

These phosphorylation events seem to accumulate throughout the course of

infection (97). These observations led to a model where T124 phosphorylation stimulates
replication, while subsequent phosphorylation at neighboring serines dampen this effect,
potentially altering LT’s activity on the viral genome to favor transcription of the capsid
genes (93).

No such analysis of MCPyV LT phosphorylation has yet been reported. We
sought to provide an initial framework for understanding the regulation of MCPyV LT’s
functions by performing a proteomic analysis to search for relevant phosphorylation sites.
Our studies identify three phosphorylation marks on MCPyV LT; T271, T297 and T299.
We found that T271 had no effect on replication, while T297 and T299 phosphorylation
had antagonistic effects. Both T297 and T299 altered the binding affinity of MCPyV for
the viral Ori while leaving unwinding and helicase functions largely intact.

Taken

together, our data reveal a dynamic interplay between multiple phosphorylation sites,
which together regulate MCPyV LT’s ability to initiate replication at the viral Ori.

2.3: RESULTS
2.3.1: Mass Spectrometry Identifies T271, T297 and T299 as Phosphorylation Sites on
MCPyV LT
Polyomavirus LT proteins perform a large variety of functions in infected cells to
establish a replicative niche; these functions include manipulation of the host cell cycle
	
  

24	
  

through its DnaJ domain and pRb binding domain, regulation of viral transcription, and
initiation of viral genome replication by acting as the viral helicase (8,31,93).
Phosphorylation of LT has been well established as a mechanism of regulating its
function, especially as a replication initiator protein.

To date, no analysis of MCPyV LT phosphorylation has been performed. To get
a broad view of MCPyV LT phosphorylation, we performed a mass spectrometry
analysis to identify potential LT phosphorylation sites. MCPyV LT was first affinity
tagged with two IgG binding domains from S. aureus Protein A and a Tobacco Etch
Virus (TEV) Protease cleavage site. This construct was then ectopically expressed in
HEK 293 cells. The protein was affinity purified on IgG-Sepharose beads, separated by
SDS-PAGE and stained with Coommassie blue (Figure 2.1A).

The visible band

corresponding to MCPyV LT was excised and analyzed by mass spectrometry.

Trypsin-digested peptides from LT were purified and analyzed by LC/MS/MS.
The peptides covered 45% of MCPyV LT and identified two unique peptides with a shift
of 80 daltons over the predicted size, indicating a potential phosphorylation modification
at T271 and T299. We repeated this analysis using a titanium oxide column to enrich for
negatively charged peptides, such as those with phosphorylated residues. The peptides
from this purification covered 25% of MCPyV LT and identified potential
phosphorylation at T271 and T297 (Table 2.1).
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To better understand how these phosphorylation modifications may regulate
MCPyV LT function, we aligned the amino acid sequence of various representative
polyomavirus LT proteins (Figure 2.1B). T271 localized to the serine rich unique region
of MCPyV LT spanning amino acids 95-290. Of the polyomavirus LT proteins analyzed,
only murine polyomavirus contains such a tract; however, it is not well conserved with
MCPyV LT. Although the lack of homology prevented us from making functional
predictions of T271 phosphorylation, it is interesting to note this threonine was identified
by multiple peptides in both mass spectrometry purification schemes (Table 2.1), giving
us high confidence that this site is phosphorylated when LT is expressed in cells.

Threonine 297 is not well conserved amongst polyomavirus LT proteins. Its
function was not readily apparent to us based on homology, although its close proximity
to the OBD led us to predict that it might have some impact on viral replication.
Modeling of the OBD (aas 308-433) using the structure published by Harrison and
colleagues (Figure 2.2A) (28), and extending their structure to include this threonine
supported this hypothesis; T297 appears to face the protein/DNA interface and might
even make direct contacts with DNA (Figure 2.2B). In contrast to the two threonines
discussed above, T299 is a highly conserved site found in all polyomavirus LT proteins
analyzed. The homologous site in SV40 LT, T124, has been well established as a key
regulator of LT mediated DNA replication. Phosphorylation of this threonine in SV40 is
thought to regulate double-hexamer interactions on the viral origin to stimulate
unwinding and melting of the DNA. Alanine substitutions of this site in SV40 LT
completely abolish LT-mediated DNA replication. Our modeling of the OBD showed
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that this threonine does not directly face the protein/DNA binding interface and likely
plays a role in protein-protein interactions between LT monomers and/or hexamers
(Figure 2.2C). The crystal structure of the MCPyV OBD was solved in complex with
DNA; since this structure did not include the T299 residue, we cannot rule out the
possibility that T299 may interact with DNA in steps prior to hexamer assembly on the
origin.

The sequence analysis and modeling led us to believe that phosphorylation of at
least a subset of the threonines identified would play a role in viral DNA replication. Our
lab has previously studied MCPyV LT-mediated replication in C33A cells, an HPVnegative cervical cancer cell line; we therefore took advantage of this system to probe the
potential roles of these threonines in viral DNA replication.
2.3.2: MCPyV LT Phosphorylation Affects the Formation of Viral Replication Centers
To begin elucidating the role(s) these phospho-sites might play in replication, we
generated alanine point mutants at each threonine identified by the mass spectrometry
analysis. We then co-transfected these constructs with a plasmid containing the MCPyV
Ori into C33A cells and stained these cells for LT and various replication factors, as has
been described in our previous study (50). We assessed these mutants for their ability to
form viral replication centers, which appear as nuclear foci, in transfected nuclei by IF.
We also assessed their ability to recruit factors known to co-localize with MCPyV
replication foci, including Brd4, RFC1 and RPA70.
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As has been shown previously, wild-type (WT) LT formed punctate foci in nuclei
when co-transfected with a construct containing the MCPyV Ori. Our previous studies
have confirmed that under these transfection conditions these foci contain the MCPyV
Ori plasmid (as shown by FISH) and are actively replicating (assessed by incorporation
of BrdU) (49). Both the T271A and T297A mutants formed replication foci while
T299A completely failed to assemble replication foci (Figure 2.3A-C). The T271A and
T297A mutant LT proteins formed replication foci at altered rates. Compared to WT LT,
which formed replication foci in about 15% of LT positive nuclei, the T271A mutant had
a small decrease in the frequency of replication focus formation (about 10%) (Figure
2.3D). This difference, however, was not statistically significant in a one-way ANOVA
test. In contrast, the T297A mutant exhibited twice as many LT-positive nuclei with
replication foci. For constructs which formed replication foci, recruitment of cellular
factors did not seem to be affected; WT, T271A and T297A LT proteins all recruited
Brd4, RFC1 and RPA70 proteins at similar rates. Colocalization with T299A, which did
not form replication foci, was not evident (Figures 2.3 and 2.4). As has been seen
previously, replication foci came in a variety of sizes, and nuclear swelling was often
evident, especially in cells expressing T297A LT, possibly to accommodate rapidly
replicating plasmids.
2.3.3: MCPyV LT Phospho-mutant Proteins Have Altered Replication Capacities
Our IF studies indicated that at least a subset of the threonines identified in our
proteomic analysis affect viral genome replication. To more rigorously examine these
mutants’ ability to replicate plasmids containing the viral Ori, we performed Southern
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blotting experiments to detect replicated plasmids. C33A cells were co-transfected with a
MCPyV LT construct and a plasmid containing the viral Ori.

Two days after

transfection, cells were harvested and divided into two fractions. Whole genomic DNA
extracts were prepared from one fraction while proteins were collected from the other
fraction. Whole genomic DNA was then digested with BamHI to linearize the plasmids.
The DNA was then detected with
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P-labeled MCPyV Ori plasmid as a probe. The LT

expression construct is made from the same vector backbone as the MCPyV Ori plasmid,
and is therefore detected as a second, higher molecular weight band in our Southern blot.
Additionally, the vector control for MCPyV LT is almost identical in size to the MCPyV
Ori plasmid, so these two plasmids co-migrate as one band in our blots (Figure 2.5A,
bottom). Whole genomic DNA was also digested with DpnI to reveal newly replicated
DNA (Figure 2.5A, top).

The Southern blotting results complemented what was seen by IF (Figure 2.3 and
2.4). Compared to WT MCPyV LT, the T271A mutant replicated the MCPyV Ori
plasmid almost as well. In contrast, the T297A mutant, which had twice as many nuclei
with replication foci as WT (Figure 2.3D), had a robust replication phenotype that was
well over that seen for WT. This was especially striking given that both the amount of
MCPyV Ori input plasmid and the protein level of T297A LT was less than WT (Figure
2.5). Finally, the T299A mutant, which failed to form replication foci as seen by IF, was
unable to replicate Ori plasmids at a level detectable by Southern blot (compare Figure
2.5A, top panel, Vector and T299A lanes). This agrees with what was seen in SV40,
where the homologous mutant, T124A, failed to replicate viral genomes.
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2.3.4: T297A and T299A Phospho-mutant LT Proteins Bind the Viral Ori with Altered
Affinity
Our studies up to this point confirmed that the T297A and T299A mutants had
greatly altered replication phenotypes; T271A by contrast showed a modest effect on
replication. To get a firmer understanding of the molecular basis for the replication
phenotypes we observed, we next sought to examine the binding, unwinding and helicase
activities of these mutants. We focused our analyses on the T297A and T299A mutants,
which had dramatic replication phenotypes.

Polyomavirus LT binding of the viral Ori is mediated by its OBD, which
recognizes GAGGC pentanucleotide repeats in the Ori. The MCPyV Ori more closely
resembles that of murine polyomavirus; it contains eight perfect GAGGC
pentanucleotides and two imperfect pentanucleotides, with two A/T rich regions
interspersed between these repeats (Figure 2.6A) (10,28,82).

Previous studies have

shown that pentanucleotides 1, 2, 4 and 7 are essential for replication (10).

To test origin binding, we performed electromobility shift assays (EMSA).
Affinity tagged MCPyV LT constructs were transfected into HEK 293 cells. Forty-eight
hours later, LT proteins were immunopurified and cleaved with TEV protease (Figure
2.6B). Various amounts of purified proteins were then incubated with a 32P-labeled PCR
product encompassing all ten pentanucleotides and one of the two A/T tracts (Figure
2.6A, EMSA probe). Previous work with the SV40 Ori demonstrated that using Ori
probes that lacked either the A/T rich tract or early palindrome region of the Ori revealed
30	
  
	
  

a defect in double hexamer formation for T124A mutants (73). We predicted that the
T299A mutant would exhibit a similar double hexamer defect in similarly altered Ori
probes; however, given that one of the key pentanucleotides required for MCPyV
replication (#7) lies outside one of the two A/T rich tracts of the MCPyV Ori, it was
impossible to directly copy the unique architecture of the artificial probes generated in
that study (10,73,98). Following these observations, we chose to omit one A/T tract but
retain all ten pentanucleotide repeats in the hopes of seeing this phenotype. In addition,
the ATP analogue AMP-PNP was included to stimulate hexamer formation but inhibit
ATPase activity, which would unwind the double-stranded probe (62). Protein/DNA
complexes were resolved on a non-denaturing polyacrylamide gel in TBE.

All mutant MCPyV LT proteins were able to bind the probe, albeit with different
affinities. The WT LT showed robust binding beginning at 1µg purified protein; probe
binding was further enhanced when more LT was added (Figure 2.6C). In contrast, the
T297A mutant achieved maximal probe binding at 0.5µg, indicating a more robust
affinity for this probe than WT. This phenotype agrees with the previous observation that
this mutant replicates plasmids with the MCPyV Ori to a high degree (Figures 2.3 and
2.5). On the other hand, the T299A mutant exhibited an attenuated affinity for the EMSA
probe; only at the highest dose (1.5µg) was binding evident, and still not to the level of
either WT or T297A LT proteins. Our EMSA studies with T299A did not reveal single
hexamers, which would migrate faster than the double hexamers binding our probe. It is
possible that T299A does not have a double hexamer defect like its SV40 homologue, or
that the probe used in our study was not sufficiently small to reveal such a phenotype.
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Native PAGE analyses of these proteins was unable to resolve this question (data not
shown). The technical limitations of our assay therefore preclude making any statements
about the ability of these mutants to form single or double hexameric complexes. The
attenuated binding phenotype for the T299A mutant, however, agrees with the
observation that this mutant fails to replicate plasmids containing the viral Ori (Figures
2.3 and 2.5) and agrees with what has been reported for SV40 LT T124A binding (99).

2.3.5: MCPyV Phospho-mutant LT Proteins Exhibit Similar Unwinding and Helicase
Activities
After initial binding of the viral Ori, polyomavirus LT proteins form two
hexameric complexes that then untwist and unwind the origin DNA to form an initial
bubble of single-stranded DNA (61,64,69). To test these mutants for their ability to
unwind a double-stranded Ori sequence, we generated a probe that contained both A/T
tracts and the first eight pentanucleotide repeats (Figure 2.7A, Unwinding Probe). This
probe was generated by annealing two oligonucleotides which form a duplex with a four
nucleotide overhang; this overhang was filled in with the Klenow fragment of DNA
Polymerase and
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P-labeled dCTP, generating a double stranded probe with one labeled

strand. This probe was then incubated with purified MCPyV LT in conditions that
promote ATPase activity. Reactions were then stopped with the addition of SDS and
EDTA, and the DNA was resolved on a non-denaturing polyacrylamide gel. All LT
constructs were able to unwind the probe (Figure 2.7B).

This result was helicase

dependent, because an MCPyV LT mutant, E627A, that we have previously described
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failed to unwind our probe (Figure 2.8) (14). The T297A mutant, which showed a high
affinity for the Ori (Figure 2.6C) showed unwinding activity similar to WT LT; because
WT LT’s activity was close to maximal unwinding in this assay (compare Boiled Control
lane with WT LT lanes, Figure 2.7B) we are unable to say whether this mutant might
have increased unwinding activity over WT activity. We also tested whether MCPyV LT
could unwind a mutated Ori sequence. We introduced the Ori350 point mutation to
pentanucleotide 7 in our assay; this mutation was reported by our lab and others to have
partially abrogated replication due to reduced binding of LT to the origin (Figure 2.8)
(10,92). LT was still able to unwind this mutant sequence; this is likely because either
the amount of LT protein used in our in vitro settings, or the extended reaction time (1hr)
compared to the EMSA (20min) can compensate for the reduced binding of LT to this
mutant Ori.

Following unwinding of the viral Ori, hexameric LT complexes then function as a
DNA helicase that translocates along DNA to separate double stranded DNA (100). To
test this function, we employed a helicase assay that has been previously reported from
our lab (14). This assay uses a circular, partially duplex DNA substrate as a probe for LT
helicase activity. The probe does not contain MCPyV Ori sequences; DNA binding is
mediated by non-specific interactions in the helicase domain. The reaction is carried out
with affinity purified LT proteins still immobilized to the affinity resin. After washing
bound proteins, half of the resin with bound LT protein was boiled in sample buffer and
western blotted to detect protein levels (Figure 2.7C). The other half of the resin was
incubated with the
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P labeled probe in reaction buffer. Helicase activity separates the
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labeled oligonucleotide from the circular template, allowing the probe to migrate faster
during electrophoresis (Figure 2.7D).

Our results show that the mutant MCPyV LT proteins had similar helicase activity
as WT LT (Figure 2.7D). In the conditions used, WT LT was able to maximally unwind
the labeled probe; therefore we cannot conclude whether either of the mutants had
enhanced helicase activity from this assay. Interestingly, the T299A mutant, which failed
to replicate the viral origin (Figure 2.5) did not have attenuated helicase activity in this
experiment. This has been previously reported for the T299A homologue in SV40 LT,
indicating that this mutant’s helicase functions remain intact, and the block to replication
is primarily due to an inability to bind the origin efficiently (Figure 2.6C) (94). In
contrast, the T297A mutant likely replicates to a high degree solely due to an increased
affinity for the origin, as its unwinding and helicase activities were not markedly different
from WT LT. Taken together, our data indicate that T297 phosphorylation plays a direct
role in binding of the origin, while T299 phosphorylation affects both origin recognition
and possibly initial unwinding of the origin DNA, similar to its function in SV40 LT.

2.4: DISCUSSION
Merkel Cell Polyomavirus is the first human polyomavirus linked to a human
cancer. As such, it has garnered a considerable amount of interest, especially with
regards to its oncogenic potential and its causative role in MCC. Much of the basic
virology of MCPyV, in contrast, has been lacking, in large part due to the difficulty in
propagating the virus and the lack of a natural host cell line. Previous work from our lab
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has established that MCPyV LT interacts with the host DNA damage response
machinery, potentially to regulate viral genome replication (92). Understanding how
polyomavirus replication is regulated will be critical for understanding the very early
steps of MCPyV-induced transformation and oncogenesis.

Phosphorylation has been a well-established mechanism of regulation for SV40
LT activities, especially for genome replication. In addition, MCPyV LT has a unique
stretch of amino acids that is rich in serines and threonines, offering many new potential
phosphorylation sites and therefore mechanisms of regulation. To search for relevant
sites in a relatively unbiased fashion, we performed a proteomic analysis of ectopically
expressed MCPyV LT (Figure 2.1 and Table 2.1).

This analysis identified three

threonines that are likely phosphorylated when MCPyV LT is expressed: T271, T297 and
T299. We generated alanine substitutions of these sites to probe their function.

T271 was immediately interesting to us for a variety of reasons.

It was

independently identified in multiple peptides in both standard and titanium oxide
purifications (Table 2.1), providing us with a high degree of confidence that this site is
phosphorylated in cells. More intriguing, this site is located in the unique region of
MCPyV LT (aa 95-290). It does not have any homologies to other polyomavirus LT
proteins analyzed (Figure 2.1B). We anticipate phosphorylation at this site may represent
a novel function that MCPyV has acquired. Efforts thus far, however, have not revealed
what those functions may be. The T271A mutant’s ability to bind Brd4 and activate the
host DDR is similar to that seen for WT LT (data not shown). Additionally, this mutant
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was able to form replication foci and replicate plasmids containing the Ori almost as well
as WT (Figures 2.3 and 2.5). Additional experiments will be performed to identify its
role in MCPyV infection.

T299, in contrast, is highly conserved among all polyomavirus LT proteins
analyzed (Figure 2.1B). This site is homologous to T124 in SV40 LT, which has been
extensively studied for its role in regulating SV40 LT-mediated DNA replication.
Alanine substitution of this site in SV40 LT completely abrogated replication.
Biochemical analysis of T124A mutants showed that it had somewhat impaired doublehexamer interactions and unwinding activity (68,73). More importantly, its ability to
unwind duplex Ori DNA was abrogated while basic helicase activity remained
unperturbed (68). In line with these findings, T299A in MCPyV LT also failed to
replicate plasmids containing the viral Ori (Figure 2.5) and did not form replication foci
(Figure 2.3).

This mutant had a reduced capacity to bind the viral Ori in EMSA

experiments (Figure 2.6). Although studies of the homologous LT mutant, T124A, in
SV0 demonstrated that unwinding of the origin was attenuated, we were unable to
reproduce this finding in our studies (94). While is is possible that MCPyV LT behaves
differently from other polyomavirus LT’s, we believe techcinal limitations in our hands
are more likely responsible for not seeing this phenotype in MCPyV T299A LT. Its
helicase activity remained identical to wild-type (Figure 2.7D), which has been reported
for T124A LT in SV40 (94). Our EMSA studies did not indicate an attenuated doublehexamer phenotype as shown by Barbaro and colleagues for SV40 LT (73), and the
unwinding phenotype we observe is extremely subtle. It is possible our experimental
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conditions are not conducive for revealing these phenotypes, or (less likely) that T299
phosphorylation behaves in a slightly different biochemical manner than T124 in SV40
LT. We conclude that phosphorylation of T299 is required for MCPyV LT to initiate
replication of its genome in ways similar to T124 phosphorylation in SV40.

T297 was not well conserved among the polyomavirus LT proteins analyzed.
Modeling of this site seemed to indicate that this residue might face and even interact
with DNA when the LT OBD engages the viral genome (Figure 2.2B). We speculated
this site might have an impact on DNA replication. Indeed, the T297A mutant had twice
as many LT-positive nuclei exhibiting replication foci as WT LT (Figure 2.3D).
Supporting this observation, Southern blotting of in cellulo replication products showed
that this mutant replicated plasmids containing the viral origin to a very high degree
(Figure 2.5). Biochemical analyses revealed a strikingly robust affinity for the viral Ori
(Figure 2.6), while unwinding and helicase activities remained largely unaffected (Figure
2.7). These data indicate that phosphorylation of this site would dramatically decrease
LT’s capacity to bind the viral Ori, which would presumably limit its ability to initiate
viral replication. These observations are in line with our structural model (Figure 2.2)
predicting that this site faces the OBD/DNA binding interface. The negative charge of a
phosphate moiety at this site would presumably clash with the negatively charged
phosphate-backbone of DNA, leading to reduced DNA binding. SV40 has also been
reported

to

have

phosphorylation

sites

that

negatively

impact

replication.

Phosphorylation at serines 120 and 123 was shown to have a negative effect on
replication (74). Threonine 297 may provide a similar regulatory function for MCPyV
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LT. It is possible that phosphorylation at a site neighboring the stimulatory threonine
(124 for SV40 LT, 299 for MCPyV LT) may be a general feature of polyomavirus LT
proteins to limit Ori recognition and to provide a brake for viral replication.

We attempted to generate phosphomimetic mutants (threonine to aspartate or
glutamate) of these sites to probe these dynamics more closely; however, these mutants
behaved just like alanine substitutions (data not shown). Interestingly, a MCPyV LT
expression construct containing both T297A and T299A mutations matched the T299A
phenotype completely: it failed to form replication foci or replicate plasmids with viral
Ori’s (data not shown). The T297A mutation would allow for enhanced binding of the
origin (Figure 2.6), but the T299A mutation, which likely acts at steps after Ori binding
during initiation of replication, completely abrogated replication of this double mutant
(data not shown).

Taken together, our data support a model where T299 and T297 phosphorylation
act as antagonistic ON and OFF switches for replication, respectively. We would
hypothesize that T299 is first phosphorylated to stimulate viral replication, while
subsequent phosphorylation at threonine 297 would abrogate Ori recognition and
presumably reduce viral genome replication, possibly in favor of late gene expression
and/or packaging. Phosphatases may also play a role, either removing phosphates from
T299 to halt replication or from T297 to allow replication to continue.

Without

antibodies specific for phosphorylation at these sites, it is difficult to track when these
sites become phosphorylated during infection or to begin searching for the kinases that
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add these marks during infection. Analysis of the amino acid sequences of these sites
offer some clues. For SV40, cdc2/CDK1 was shown in vitro to be responsible for
phosphorylation at T124, the homologue to MCPyV LT T299 (71).

The residues

surrounding both MCPyV LT T299 and SV40 LT T124 (TPPK for both viruses, see
Figure 2.1B) exhibit a classic cdc2/CDK1 consensus sequence (S-P-X-basic residue)
(101). Although it was not directly tested here, it is likely that cdc2/CDK1 plays a role in
phosphorylating T299 during MCPyV infection.

Casein kinase II was also shown to

phosphorylate nearby serine residues in SV40 LT in vitro, which played a role in SV40
LT nuclear import (102-105). Finally, ATM kinase has been shown to phosphorylate
SV40 LT in this region as well, contributing to LT-mediated replication (81). The
threnonines T271 and T297 identified in this study do not exhibit homologies to the
known consensus sequence of either of these kinases, indicating that other kinases are
likely involved. Finally, other MCPyV viral proteins, like sT antigen, 57kT antigen and
ALTO (44), may affect when, where and how LT is phosphorylated during the viral life
cycle. These questions should be explored further as more reagents and cell lines become
available for MCPyV studies.

One of the hallmark features of MCPyV LT in MCC is that the protein frequently
becomes mutated such that it is expressed in a truncated fashion (9). These truncations
almost always delete the helicase domain and the OBD.

Interestingly, the three

phosphorylation sites identified in this study are almost always omitted from the
truncated proteins as well. It has been hypothesized that LT becomes truncated to avoid
replicating the integrated viral genome, which would presumably cause genomic
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instability (3). In line with this reasoning, at least one MCPyV related MCC tumor has
been identified with a full-length LT protein but the integrated viral genome contains a
mutated Ori that fails to support viral replication (9,10). Given that mutation of T299
completely abolishes LT’s capacity to replicate the viral origin, it is interesting to note
that this mutation has never been observed in any of the MCC cases studied thus far. It is
possible that the OBD, helicase domain and/or extreme C-terminal domain contain
additional activities beyond replication that are negatively selected out during MCC
progression. Our previous studies have indicated that the C-terminal half of MCPyV LT
interacts with the p53 pathway to maintain cells in a stalled S-phase, which may be
conducive to viral genome replication but antithetical to tumorigenesis (14). Others have
similarly postulated that the C-terminal domain contains activities beyond replication that
are negatively selected during MCC oncogenesis (13). Further investigation of this
region of the protein may provide a broader and more comprehensive understanding of
how MCPyV LT manipulates the host cell, and how these activities become disrupted
during MCC tumorigenesis.

2.5: FIGURES
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TABLE 2.1

TABLE 2.1: Phosphorylated peptides Identified by mass spectrometry. Shown are
the reconstructed peptides isolated by both the standard purification and titanium oxide
enrichments after trypsin digest. Confidence in identification is given as a probability.
The residues in bold are the ones identified as having a mass value 80 daltons higher than
predicted, indicating a phosphorylation modification.
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FIGURE 2.1
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Figure 2.1: Identification of MCPyV LT phosphorylation sites. (A) Affinity-tagged
MCPyV LT was transfected into HEK 293 cells. Forty-eight hours post transfection,
lysates from transfected (LT) or untransfected (Mock, M) cells were purified with IgGSepharose beads. Bound proteins were cleaved from beads with TEV protease, separated
by SDS-PAGE and stained with Coommassie brilliant blue. The band corresponding to
MCPyV LT (*) was excised and analyzed by mass spectrometry. L – Protein Marker
ladder. (B) Alignment of the N-terminal portion of various polyomavirus LT proteins.
The three phosphorylated threonines identified by the proteomic analysis in (A) are
indicated by the red asterisks (*). Conserved residues are highlighted in blue (60%
conservation).
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FIGURE 2.2

	
  
Figure 2.2: Modeling MCPyV LT’s interaction with DNA. (A) Phyre2 and PyMOL
software was used to model the MCPyV LT protein origin binding domain (OBD)
contacting DNA as reported by Harrison and colleagues (28). The asterisks indicate the
loop of the OBD that makes contacts with DNA. (B) The structure modeled in (A) was
extended to aa 290 and modeled using Phyre2 and PyMOLsoftware. The model was
rotated to match the orientation of the structure in (A). T297 is highlighted in red and
appears to face – and possibly contact – DNA. (C) The same model in (B) was labeled to
show T299, which appears to face away from DNA, possibly to interact with adjacent LT
monomers or hexamers. Valine 311 is labeled in all three structures to aid in comparison.
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FIGURE 2.3
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Figure 2.3: MCPyV LT phospho-mutant proteins form viral replicaiton foci at
altered efficiencies. (A-C) C33A cells were co-transfected with an MCPyV Ori plasmid
and the indicated MCPyV LT phospho-mutant. Forty-eight hours post transfection, cells
were fixed and stained for LT (green) and the indicated cellular factor (Red). Nuclei
were counterstained with DAPI. Bar = 3µm. (D) Nuclei stained positively for LT as
shown in (A-C) were scored for the presence of viral replication foci (at least 150 LT
positive nuclei were counted in triplicate per transfection).

Bar indicates standard

deviation from the mean from at least three independent experiments.

Statistical

significance was calculated against WT LT using a one-way ANOVA (*** p < 0.0001).
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FIGURE 2.4

FIGURE 2.4: MCPyV phospho-mutant LT proteins recruit cellular factors to the
same degree. Replication foci scored in Figure 2.3 A-C were assessed for colocalization
of the indicated cellular factors. Bar indicates standard deviation from the mean from
three independent experiments. A one-way ANOVA was performed to determine
significance (** p < 0.001).
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FIGURE 2.5
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Figure 2.5: MCPyV LT phospho-mutant proteins replicate plasmids containing the
viral Ori to differing degrees. C33A cells were co-transfected with a MCPyV Ori
plasmid and the indicated MCPyV phospho-mutant LT. Forty-eight hours post
transfection cells were split and extracted for total cellular DNA or total proteins. (A)
Southern blotting of whole genomic DNA. Both the MCPyV Ori and MCPyV LT
plasmids use the same vector backbone and are both recognized by the Southern blot
probe. 15 µg of DNA was digested with BamHI and DpnI to detect replicated origin
plasmid (Replicated Products, top); replicated Ori plasmid is indicated. 2 µg of DNA
was digested with only BamHI to show equal loading (Input, bottom); Ori and LT
plasmids are indicated. The vector control plasmid for LT is almost identical in size to
the Ori plasmid, causing both plasmids to co-migrate in the blot (asterisk, first lane,
bottom panel). (B) Total protein extracts were Western blotted to detect MCPyV LT and
GAPDH. Southern and Western blots are representative of at least three experiments.
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FIGURE 2.6
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Figure 2.6: MCPyV LT phospho-mutants bind the viral Ori with different affinities.
(A) Schematic of the MCPyV Ori and the EMSA Probe. Only one strand of DNA is
shown for clarity. The MCPyV Ori sequence was cloned from the R17a isolate of
MCPyV into a pcDNA4c vector (50). This origin was used for replication assays (Figure
2.3, 2.4, and 2.5). Consensus GAGGC pentanucleotide repeats which are recognized by
the OBD of LT are marked with arrows and numbered as was reported by Kwun et al.
(10). Arrows with dashed lines indicate imperfect pentanucleotides. The EMSA Probe
was generated by PCR amplification of the indicated region of the MCPyV Ori. This
PCR product was 5’ end-labeled with [32P-γ] ATP using T4 polynucleotide kinase
(indicated by red asterisk). (B) Western blot of purified MCPyV proteins (0.25µg) used
in EMSA. The buffer control contained residual TEV protease (also in LT samples). (C)
Electromobility shift assays were performed with the EMSA probe in (A) and increasing
amounts of MCPyV wild type or phospho-mutant LT affinity purified from HEK 293
cells. Reactions with buffer and residual TEV protease served as a negative control (first
lane). Positions of free probe and LT bound probe are indicated. Data in (B) and (C) are
representative of at least three experiments.
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FIGURE 2.7
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Figure 2.7: MCPyV LT phospho-mutants have similar unwinding and helicase
activities. (A) Schematic of the Unwinding Probe. The Unwinding Probe was generated
by annealing two complimentary oligonucleotides spanning the indicated sequence. The
duplexed oligo contains a four-nucleotide overhang that was filled in by Klenow and
[32P-α] dCTP so that only one strand was labeled. The filled-in nucleotides are marked in
bold, and the radiolabeled dCTP is indicated by an asterisk. The MCPyV Ori sequence
depicted in Figure 2.6A is shown for reference. (B) Unwinding assays were performed
with varying amounts of affinity purified MCPyV LT (wild-type or phospho-mutant).
Samples without purified protein served as a negative control. One sample was boiled to
show the migration of unbound probe. Data are representative of three independent
experiments.

(C, D) Constructs expressing affinity tagged MCPyV wild-type or

phospho-mutant LT were transfected into 293 cells. Proteins were harvested 48 hrs posttransfection and LT was immunopurified on IgG-conjugated beads. Half of the beads
with bound LT were boiled in sample buffer and resolved on an SDS-PAGE followed by
Coommassie staining (C) while the remaining beads were used in the helicase assay (D).
Beads incubated with 1% bovine serum albumin served as a negative control (BSA).
Helicase reaction mix incubated at room temperature (Control) or at 95˚C for 5min
(Boiled Control) served as controls for partially duplex and unwound substrate,
respectively. Data shown are representative of at least three independent experiments.
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FIGURE 2.8

FIGURE 2.8: Unwinding assay performed with a helicase mutant LT and a mutated
Ori probe. Unwinding assays were performed with both wild-type LT and the E627A
mutation, which abolishes helicase activity. In parallel, an origin probe with a mutation
in the seventh pentanucleotide repeat which abolishes origin-dependent replication
(Ori350) was also tested using wild-type MCPyV LT. Data shown are representative of
two repeats.
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CHAPTER 3: PHOSPHORYLATION OF MERKEL CELL POLYOMAVIRUS
LARGE T ANTIGEN AT SERINE 816 BY ATM KINASE INDUCES APOPTOSIS
IN HOST CELLS

Dr. Jing Li was the primary investigator for this project, and was responsible for
the design and execution of most of the experiments. I assisted in screening various LT
truncation and point mutants to show that the C-terminal half of LT was recognized by
the phospho-Chk1 antibody (Figure 3.1 and data not shown). I also designed and
performed the CIP experiment to show that this cross-reactive antibody recognized a true
phosphorylation mark, and helped confirm that S816 was the phosphorylation site (Figure
3.2). I later assisted in testing whether S816E was a phosphomimetic. Dr. Xin Wang
assisted in performing the in vitro phosphorylation assay, while Sabrina Tsang assisted
with the ATM pulldown experiment (Figure 3.4). All other experiments were performed
by Jing. I prepared the manuscript and made major contributions to the experimental
design of the manuscript.

Jing Li, Jason Diaz, Xin Wang, Sabrina H. Tsang, and Jianxin You. Phosphorylation of
Merkel Cell Polyomavirus Large T Antigen at Serine 816 by ATM Kinase Induces
Apoptosis in Host Cells. Journal of Biological Chemistry 2014; Epub Ahead of print
DOI: 10.1074/jbc.M114.594895 © the American Society for Biochemistry and Molecular
Biology
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3.1: CHAPTER SUMMARY
During the preparation of an earlier manuscript (Jing Li et al., Journal of Virology
(2013) 87: 9173-88), we noticed that an antibody raised against phosphorylated serine
345 of the cellular kinase Chk1 had cross reactive bands identical in size with ectopically
expressed MCPyV LT constructs specifically retaining the C-terminus. We showed that
this cross-reactivity was through a true phosphorylation mark sensitive to phosphatase
treatment, and screened a number of candidate point-mutants to finally localize this mark
to serine 816 of LT. Since the cross-reactive antibody targeted a kinase involved in the
DDR, we asked whether phosphorylation of S816 was mediated by DDR pathways.
Pharmacological treatment to activate and suppress various arms of the DDR, coupled
with in vitro binding and kinase assays, indicated that the double-strand break repair
kinase ATM was likely the cellular kinase for S816 phosphorylation. The c-terminal
region of LT has been shown to have a growth-inhibitory effect, so we asked whether
S816 phosphorylation contributed to this activity. A clonogenic assay showed that the
alanine mutant S816A LT partially rescued the growth arresting properties of MCPyV
LT. Analysis of molecular markers for apoptosis also showed less cell death with
S816A. This study uncovered a novel phosphorylation site for MCPyV LT and identified
a candidate cellular kinase responsible for this modification while also implicating
growth arrest and apoptosis as functional consequences of this activity.
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3.2: INTRODUCTION
Merkel cell polyomavirus (MCPyV) is a recently identified polyomavirus that is
associated with a highly aggressive skin cancer MCC (6,8). MCPyV is associated with
approximately 80% of MCC cases (6,9,106). MCC metastasizes rapidly. It is one of the
most aggressive skin cancers with an extremely high mortality rate of 33%, exceeding the
rate of melanoma (107), and less than 45% five-year survival rate (108). The incidence of
MCC has increased from 1.5 to 6 per million people between 1986 and 2006, and
approximately 1500 new cases of MCC are diagnosed each year in the United States
(109,110). Epidemiological surveys of MCPyV antibodies and sequencing analyses of
healthy human skin have indicated that MCPyV may represent a natural component of
the human skin micro-flora (19,21,22).

Like other polyomaviruses, MCPyV encodes a single early gene, the Tumor
antigen. The MCPyV Tumor antigen is multiply spliced into the Large Tumor antigen
(LT), small Tumor antigen (sT), 57 kT, and ALTO (41,44). Similar to other
polyomaviruses, the multi-functional MCPyV LT protein is involved in a variety of
processes, including viral genome replication and host cell cycle manipulation
(14,50,111).

MCPyV LT contains conserved features of other polyomavirus LT proteins, such
as conserved region 1 (CR1), a DnaJ domain which interacts with Heat shock protein 70
(Hsc70) family members, an LXCXE pRb binding motif, an OBD, and a
helicase/ATPase domain required for viral DNA replication (9,41). The T antigens from
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several polyomaviruses have oncogenic activity. Notably, the simian virus 40 (SV40)
large and small T antigens can transform a variety of rodent and human cells (31,112). In
addition, LT from SV40 as well as the human polyomaviruses JCV and BKV can bind to
pRb and p53 tumor suppressor proteins (113-116). MCPyV LT can bind specifically to
pRb (9,32). While there are two potential p53 binding motifs on the MCPyV LT Cterminal domain, there appears to be no direct interaction between MCPyV LT and p53
(13,26). Interestingly, the MCPyV genome is commonly clonally integrated into MCC
tumor cell genomes. Almost all MCPyV LTs expressed from the integrated MCPyV
genomes harbor non-sense mutations, which result in expression of a truncated large T
that retains the N-terminal pRb binding motif but deletes the C-terminal DNA binding
and helicase domains (9).

It has been postulated that these truncated LT proteins arise because replication of
the integrated viral genome by full-length MCPyV LT may instigate a debilitating
amount of DNA damage due to abortive replication at the integrated viral origin (9). The
identification of a tumor with intact, full length LT but a mutated viral origin sequence
supports this hypothesis (10). Later studies have since suggested that the C-terminal
helicase domain may contain other functions that oppose tumorigenesis (13,14). Our
previous work indicates that expression of full-length MCPyV LT activates a dramatic
DDR that is antagonistic to tumorigenesis; this activity activates p53 and induces a
growth-inhibition phenotype (14). Additionally, Cheng et al. reported that expression of
the C-terminal 100 residues of MCPyV LT could inhibit the growth of several different
cell types (13). These studies support a model where the C-terminal domain must be
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deleted in tumor cells to both limit viral replication from the integrated viral genomes,
and eliminate growth-arresting properties intrinsic to the C-terminal domain of LT. How
the MCPyV C-terminal 100-residues accomplishes this growth-arresting function is not
clearly understood.

In addition to being stimulated by MCPyV LT expression, work from our lab has
shown that components of the host DDR are recruited to viral replication centers (49).
These factors were necessary for supporting MCPyV genome replication (49), but their
mechanism of action was not understood.

Protein phosphorylation of serines (S),

threonines (T), and tyrosines is one of the most common methods for regulating protein
function. Phosphorylation of SV40 LT on both serine and threonine residues plays an
important role in regulating LT antigen function. Phosphorylation of SV40 LT S120 and
S123 inhibits viral replication, while phosphorylation of T124 enhances replication by
activating the DNA binding domain and stimulating double-hexamer activity
(71,72,81,117,118). Phosphorylation of T701 is required for binding to the host FBW7
gamma isoform, which regulates SV40 LT protein stability (119). The studies presented
in Chapter 2 identified T271, T297 and T299 as phosphorylation sites on MCPyV LT. In
that study, we demonstrated that phosphorylation of T297 and T299 regulates MCPyV
LT-mediated replication of the viral DNA. In this current study, we identify a novel
MCPyV LT phosphorylation site at S816.

We demonstrate that this site is

phosphorylated by ataxia telangiectasia mutated (ATM) kinase, a key component of the
host DDR primarily activated by dsDNA breaks (DSBs) (120). Activation of ATM
kinase by etoposide increases MCPyV LT phosphorylation at S816. In contrast, Ataxia	
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telangiectasia and Rad3 related (ATR) kinase was unable to robustly phosphorylate
MCPyV LT. Expression of wild-type MCPyV LT inhibits cell proliferation and also
induces several cell lines to undergo apoptosis. Expression of the serine to alanine
substitution mutant MCPyV LT S816A partially rescues this growth inhibition and also
inhibits the induction of apoptosis. This report reveals that MCPyV LT is a substrate of
ATM kinase, and that phosphorylation at S816 contributes to the regulation of host cell
proliferation and apoptosis.

3.3: RESULTS
3.3.1: MCPyV LT is Phosphorylated at S816
In our previous study, we found that either MCPyV infection or transfection of
MCPyV genomes into cells activated both ATM and ATR kinases, while ectopic
expression of just MCPyV LT primarily induced the ATR-Chk1 DDR pathway in U2OS
cells (14). Interestingly, in these immunoblotting experiments we also discovered that the
anti phospho-Chk1 S345 antibody not only detected phospho-Chk1 S345 but also
recognized protein bands with molecular weights that match those of transfected LT 1817, LT 212-817, GFP-LT 441-817 or GFP-LT 1-817, respectively (Figure 3.1A and B,
bands with an arrow). This cross-reactivity was observed for all MCPyV LT truncation
mutants retaining the carboxyl terminal ~400 amino acids (Figure 3.1A and B). These
cross-reactive bands were also detected in C33A and HeLa cells (data not shown). This
antibody also recognized another cross-reactive band of about 120 kD in all samples,
regardless of LT expression (Figure 3.1B, band marked with an asterisk). SV40 LT also
activated phospho-Chk1 S345 in U2OS cells (14), but there were no cross-reactive bands
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detected in the SV40 LT sample (Figure 3.1A). Since the cross-reactive bands (marked
with an asterisk) had similar molecular weights as the ectopically expressed LTs in those
samples, we suspected that the anti-pChk1 S345 antibody specifically cross-reacts with
MCPyV LT.

To confirm that this cross-reaction was mediated by a true phosphorylation
modification, lysates from U2OS cells transfected with pcDNA4C-MCPyV LT were
treated with or without calf-intestinal alkaline phosphatase (CIP) for 30 minutes, and
analyzed by Western blot. As shown in Figure 3.2A, expression of LT 1-817 activates a
robust phospho-Chk1 S345 signal in U2OS cells, and there is again a cross-reactive band
with a molecular weight around 110 kD that matches the size of full-length MCPyV LT.
Treatment with CIP significantly diminished both the phospho-Chk1 and the 110 kD
cross-reactive signal (marked with an arrow) in the cell lysate (Figure 3.2A).
Interestingly, the other cross-reactive band of about 120 kD (marked with an asterisk)
was also diminished.

This result suggests that the phospho-Chk1 S345 antibody

recognizes a true phosphorylation modification on both the 110 kD and 120 kD crossreactive bands.

Chk1 is phosphorylated by ATR kinase at S345 in a canonical S/T-Q epitope that is
commonly targeted by ATM and ATR kinases. Assuming the cross-reactive band similar
to transfected LT was indeed MCPyV LT, the data from Figure 3.1 suggested that the
phosphorylation site was within the C-terminal 400 amino acids. We compared the
epitope recognized by the phospho-Chk1 S345 antibody with the C-terminal sequence of
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MCPyV LT and generated alanine substitutions of several potential phosphorylation
sites. These point mutants were transfected into U2OS cells and immunoblotted with the
pChk1 S345 antibody. Out of all the sites analyzed, we found that mutagenesis of S816
alone abolished MCPyV LT cross reactivity with the phospho-Chk1 S345 antibody
(Figure 3.2B and data not shown). The 120 kD cross-reactive band was unaffected when
cells were transfected with this mutant LT. Taken together, these data demonstrate that
MCPyV LT is phosphorylated at S816, and that this phosphorylation is specifically
recognized by the pChk1 S345 antibody. The 120 kD band (marked with an asterisk) is
likely a cellular phospho-protein that is also recognized by this antibody; however, we
chose to focus the remainder of our study on the phosphorylation of MCPyV LT at S816.

3.3.2 Activation of ATM Stimulates MCPyV LT S816 Phosphorylation
Having identified S816 as a phosphorylation site of MCPyV LT, we next sought
to determine which kinase(s) or kinase pathway(s) was responsible for this modification.
Our previous data showed that MCPyV virus infection and MCPyV genome transfection
activate both ATM and ATR DNA damage response pathways. In contrast, ectopic
expression of MCPyV LT alone predominantly activates ATR and only weakly activates
ATM (14,49). Additionally, we have reported that components of the host DDR
pathways are recruited to viral replication centers, and that their activity is required for
efficient replication (49). We wondered whether components of these DDR pathways
could be responsible for LT S816 phosphorylation.
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We first used etoposide or UV light to activate either ATM or ATR pathways,
respectively, and tested whether phosphorylation of LT was altered. U2OS cells were
transfected with pcDNA4C (Vec) or pcDNA4C-MCPyV LT. Forty-four hours post
transfection, cells were treated with either 4 µM etoposide for another 4 hours or treated
with 10 J UVC light. The cells were then harvested for Western blot analysis. As shown
in Figure 3.3A, expression of LT induced a mild activation of both ATM S1981
phosphorylation and Chk1 S345 phosphorylation, a surrogate of ATR activation
(compare lane 4 to lane 1 in Figure 3.3A). Etoposide treatment, which primarily activates
ATM kinase, induced dramatic activation of ATM S1981 phosphorylation as well as LT
phosphorylation at S816 (Figure 3.3A, lane 5). In contrast, UV light treatment, which
predominantly activates ATR, caused a much smaller degree of ATM phosphorylation
and very little activation of LT S816 phosphorylation compared to DMSO treatment
(Figure 3.3A, compare lane 6 to lane 4). These results demonstrated that activation of the
host ATM DDR pathway could stimulate phosphorylation of MCPyV LT at S816.
Robust phosphorylation of Chk1 S345 was seen with both etoposide and UV treatments,
indicating either that ATR was activated in both settings, or that the robust activation of
ATM during etoposide treatment allowed it to phosphorylate Chk1 through cross talk
(121-124).

3.3.3: Inhibition of ATM Prevents MCPyV LT S816 Phosphorylation
We next sought to determine which component(s) of the host DDR was
responsible for phosphorylating MCPyV LT. We tested a panel of chemical inhibitors to
screen for the possible kinases that phosphorylate MCPyV LT at S816. U2OS cells were
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transfected with pcDNA4C (Vec) or pcDNA4C-MCPyV LT. Forty-four hours later, cells
were treated with DMSO, Wortmannin, NU 6027, NU 7441, KU 55933, AZD 7762, or
caffeine for another six hours. The cells were harvested for Western blot analysis. As
shown in Figure 3.3B, the expression level of LT is constant with different drug
treatments. MCPyV LT transfected cell lysates show phosphorylated MCPyV LT S816
bands at around 110 kD; however, the band density changes with various drug treatments
(Figure 3.3B). Caffeine, which inhibits both ATM and ATR, reduced phosphorylation of
LT S816 to a small extent (Figure 3.3B). Wortmannin, which acts as a broad PI3K
inhibitor that inhibits DNA-PK, ATM, and ATR, efficiently inhibited MCPYV LT S816
phosphorylation (Figure 3.3B). On the other hand, the ATR inhibitor NU 6027, the DNAPK inhibitor NU 7441, and the Chk1 inhibitor AZD 7762, did not affect LT
phosphorylation (Figure 3.3B). These results suggests that the ATM pathway was likely
important for the LT S816 phosphorylation. Further supporting this notion, the ATM
inhibitor KU 55933 caused dramatically reduced LT S816 phosphorylation (Figure 3.3B).
These experiments were repeated in C33A cells with similar results (data not shown).
Taken together, these data suggest that ATM is likely the kinase that phosphorylates
MCPyV LT at S816.

3.3.4: ATM Kinase Binds and Phosphorylates MCPyV LT at S816 In Vitro
We then performed in vitro phosphorylation experiments to more directly confirm
that ATM kinase phosphorylates MCPyV LT at S816. An IgG-IgG-TEV (IIT) affinity
tag, comprising two IgG binding domains and a tobacco etch virus (TEV) cleavage site,
was subcloned in-frame with wild type and S816A mutant MCPyV LT for affinity
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purification (See Materials and Methods and (50)). IIT affinity tagged wild type MCPyV
LT or S816A LT was purified from 293 cells and treated with CIP to remove
phosphorylation modifications. In parallel, U2OS cells were stimulated with etoposide to
activate the host DDR, and either ATM or ATR kinases were immunoprecipitated from
nuclear extracts (Figure 3.4A). ATM or ATR was then immunoprecipitated and
immobilized on sepharose beads and incubated with radiolabeled ATP and equal amounts
of either wild type LT or LT S816A protein in kinase reaction buffer. Only wild type LT
incubated with immunopurified ATM demonstrated significant phosphorylation;
incubation with ATR did not show detectable activity above background (Figure 3.4A).
This was true when the in vitro phosphorylation reaction was performed either at room
temperature or at 37˚C. The S816A LT was not phosphorylated by either ATM or ATR
kinases, regardless of temperature (Figure 3.4A). We also confirmed that LT could
interact with ATM by pulling down ATM kinase from U2OS nuclear extracts using
immobilized, bacterially derived LT (Figure 3.4B). This binding was clearly evident
even with a relatively small amount of LT (Figure 3.4B, compare GST with GST-LT in
the CBB stain). These data, together with the kinase inhibitor screen shown in Figure
3.3B, strongly suggest that ATM is the major kinase that phosphorylates MCPyV LT at
S816.

3.3.5: Prevention of MCPyV LT S816 Phosphorylation Partially Rescues the MCPyV LT
Growth Inhibition Effect
We next sought to better understand the physiological function of the ATMmediated MCPyV LT S816 phosphorylation. We were unable to find defects in genome
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replication or viral gene transcription for MCPyV LT S816A (data not shown). Our
previous study demonstrated that the C-terminal portion of LT activates p53 and
promotes growth inhibition (14). Cheng et al. also reported that the C-terminal 100 amino
acids of MCPyV LT have a cell growth inhibition effect (13). The underlying mechanism
of these findings was not completely established.

Since the C-terminal domain of

MCPyV LT was sufficient for DDR activation (14), and because S816 lies within the Cterminal 100-amino acids region of MCPyV LT, we asked whether S816 phosphorylation
played a role in the cellular growth inhibition function of the MCPyV LT C-terminus. We
generated C33A cells stably expressing wild type MCPyV LT, S816A LT, or CherryLacI as a negative control. Using these cell lines, we performed a clonogenic assay to
detect the long-term effect of MCPyV LT and MCPyV LT S816A on cellular
proliferation. The same number of C33A stable cells were seeded in 6-well dishes and
cultured for 10 days under puromycin selection. As shown in Figure 3.5, the Cherry-LacI
stable cell line forms a large number of colonies. As reported previously (14), expression
of wild type MCPyV LT caused a significant inhibition of cell growth, resulting in
drastically reduced colony number after selection (Figure 3.5). S816A LT partially
reversed this LT growth inhibition phenotype, allowing more colonies to be formed after
the extended culture period (Figure 3.5). This result suggests that blocking MCPyV LT
S816 phosphorylation can partially rescue the LT growth inhibition activity,
demonstrating the impact of MCPyV LT S816 phosphorylation on cellular proliferation.
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3.3.6: MCPyV LT S816A Induces Less Apoptosis Than Wild-Type MCPyV LT
We consistently observed that transfection of the MCPyV LT S816A construct
led to less cell death than the wild-type MCPyV LT construct. The results of the
clonogenic assay also suggested that S816A LT might induce less cell death than wild
type MCPyV LT. We therefore tested both proteins for their ability to induce apoptosis.
We performed Annexin V staining to detect cells that express phosphatidylserine (PS) on
the cell surface, which is an early marker of apoptosis (125). GFP tagged MCPyV LT or
MCPyV LT S816A was transfected into C33A cells. The transfected cells were stained
with PE conjugated Annexin V at 24 hours post transfection. Cells were then fixed and
nuclei were counterstained with DAPI. At this time point, about 0.2% of vector
transfected cells have Annexin V staining, while 6.5% of MCPyV LT transfected cells
show positive Annexin V staining; however, only 3.8% of MCPyV LT S816A transfected
cells were Annexin V positive (Figure 3.6A and B). This result shows that MCPyV LT
S816A has decreased ability to induce cell death than MCPyV LT. Flow-cytometry
analysis also detected slightly more apoptotic cells with sub-G1 fraction in wild type
MCPyV LT transfected cells than in LT S816A samples (data not shown). These results
are consistent with the observation that MCPyV LT can more potently inhibit cell
proliferation than S816A LT (Figure 3.5).

To examine the differential activation of cell death by wild type MCPyV LT and
S816A LT at the molecular level, we performed Western blotting analyses to detect the
apoptotic marker Caspase-3 and Poly (ADP-ribose) polymerase 1 (PARP1). Caspase-3 is
activated in both the extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic
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pathways (126,127). In the intrinsic activation pathway, cytochrome-c from the
mitochondria works in combination with caspase-9, apoptosis-activating factor 1 (Apaf1), and ATP to process pro-Caspase-3 (128-130). Proteolytic processing of the inactive
zymogen into p17 and p12 fragments activates Caspase-3. PARP1 is involved in the
repair of DNA damage by adding poly (ADP-ribose) polymers onto a variety of
substrates in response to various cellular stresses (131). PARP1 is also a substrate for
caspases; during the execution phase of apoptosis, PARP1 is specifically proteolyzed by
Caspase-3 to produce a 24 kD N-terminal DNA binding domain (DBD) and a 89 kD Cterminal catalytic fragment (132). Cleavage of PARP1 by caspases is considered to be a
hallmark of apoptosis (133,134).

We transfected either C33A or HeLa cells with pcDNA4C (Vector), pcDNA4CMCPyV LT, or pcDNA4C-MCPyV LT S816A. Cells were harvested at 30 hours post
transfection and analyzed by Western blotting. As shown in Figure 3.6C and D,
expression levels of LT and LT S816A are similar. Vector transfected cells did not
exhibit cleaved Caspase-3 and only showed background level of cleaved PARP1,
indicating little apoptosis in these conditions (Figure 3.6C and D). Wild type LT
transfected cells have less intact PARP1, but more cleaved PARP1 as well as more
cleaved Caspase-3 than the empty vector samples, confirming the induction of apoptosis
(Figure 3.6C and D). In contrast, the levels of cleaved PARP1 and cleaved Caspase-3 in
the MCPyV LT S816A transfected cells were reduced to nearly the vector control level
(Figure 3.6C and D). These results are consistent with the observation that MCPyV LTpositive cells are more likely to undergo apoptosis than MCPyV LT S816A-positive cells
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(Figure 3.6A and B). These results support the rescue of cell growth inhibition phenotype
seen in the clonogenic assay (Figure 3.5). We also tested whether the S816E mutant
would act as a phosphomimetic, and presumably induce more apoptosis. Unfortunately,
LT S816E behaved identically to the alanine mutant and therefore was not a viable
phosphomimic (data not shown); this phenomenon has occasionally been reported for
other phosphoproteins, including SV40 LT and MCPyV LT at other phosphosites
(135,136). Taken together, these data suggest that phosphorylation of LT at S816
contributes to growth-arrest and apoptotic induction mediated by the C-terminal domain.

3.4: DISCUSSION
Most MCPyV-related MCC tumors examined thus far contain clonally integrated
MCPyV genomes, which express truncated LT proteins that omit the C-terminal domain
(9). This observation suggests a strong selective pressure to eliminate the C-terminal
region of MCPyV LT during MCC tumor development. These tumor specific mutations
do not affect LTs pRb binding domain or DnaJ domain (6). In fact, these LT mutants
even have an increased affinity for pRb (26). Work from our lab and others suggest that
the C-terminal domain of MCPyV LT might be negatively selected during tumorigenesis
to eliminate growth inhibitory properties encoded in this region (13,14).

Our previous report shows that inhibition of cellular proliferation by the Cterminal half of MCPyV LT is linked to its ability to activate the host DDR pathways
(14). In those experiments, we consistently detected cross-reactivity of the monoclonal
anti-pChk1 S345 antibody when MCPyV LT constructs were expressed. In this report,
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we explored the nature of this cross-reactivity. The cross-reactive bands correlated with
the sizes of ectopically expressed full-length MCPyV LT or LT C-terminal mutants
(Figure 3.1), and were sensitive to phosphatase treatment (Figure 3.2A), making us
suspect that this antibody recognized a phosphorylation modification on MCPyV LT.
This cross-reaction seemed to be localized to the C-terminal half of the protein (Figure
3.1). Alanine substitutions of candidate serines and threonines further identified S816 as
the target of phospho-Chk1 S345 cross-reaction (Figure 3.2B).

Our previous studies demonstrated that MCPyV LT activates the host DDR
proteins, which are recruited to actively replicating viral genomes (14,49). The crossreactive phospho-Chk1 S345 antibody was generated against Chk1 phosphorylated at
serine 345, an ATR kinase phosphorylation site. We therefore asked whether the DDR
kinases were responsible for the phosphorylation of MCPyV LT at S816. Activation of
ATM kinase with etoposide caused dramatic stimulation of MCPyV LT phosphorylation.
On the other hand, UV treatment, which predominantly activates the ATR pathway, had
little stimulating effect on MCPyV LT S816 phosphorylation (Figure 3.3A). A screen
with multiple DDR kinase inhibitors further supported the hypothesis that ATM kinase
was the predominant member of the DDR pathways responsible for this modification
(Figure 3.3B). In vitro phosphorylation of MCPyV LT with immunopurified ATM and
ATR confirmed that ATM phosphorylates MCPyV LT at S816, but ATR cannot (Figure
3.4A).

Additional pull-down experiments suggested that ATM and LT can indeed

interact (Figure 3.4B). Together with our published results (14,49), this present study
suggests that MCPyV is not only able to induce DDR in cells but can also take advantage
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of this DDR activity and recruit a cellular DDR kinase, ATM, to phosphorylate its own
LT at S816.

We next sought to understand the physiological role of this phosphorylation mark.
Although S816 lies C-terminal to the helicase domain, no effects were seen on viral
genome replication or transcription (data not shown). We therefore asked whether LT
S816 phosphorylation contributes to the growth inhibitory activity that was localized to
the final 100 residues of this protein (13). Interestingly, the growth inhibitory effect seen
with wild type LT was partially reversed with LT S816A in a clonogenic assay (Figure
3.5). The cellular proliferation phenotype was supported by an analysis of apoptosis
during LT expression. Annexin V staining and Western blot analyses of Caspase-3 and
PARP1 cleavage showed that S816A LT induced less apoptosis in transfected cells
(Figure 3.6). These results demonstrated that the ATM-mediated phosphorylation of
MCPyV LT at S816 contributes to a mechanism that inhibits cellular proliferation by
inducing cellular death.

Although this study establishes a direct functional interaction between ATM
kinase and MCPyV LT, the precise role for this interaction remains elusive. ATM is a
serine/threonine protein kinase that is recruited to and activated by DNA double-strand
breaks to phosphorylate several key cellular proteins that initiate the activation of the
DNA damage checkpoint (137-139).

This checkpoint activation results in the

phosphorylation and activation of p53, which in turn up-regulates the expression of key
cellular factors involved in cell cycle arrest, DNA repair, and apoptosis (137-139). The
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cell proliferation effects reported here when MCPyV LT is expressed could therefore be
partially due to ATM activity and represent a host response to foreign DNA replication;
indeed, the effects of blocking MCPyV LT S816 phosphorylation on cell proliferation are
modest and S816A LT was unable to fully rescue the proliferative defect in C33A cells
stably expressing LT (Figure 3.5), indicating that S816 phosphorylation-independent
mechanisms are at play.

Our previous report and current study show that transfected LT only induces a
very low level of ATM activation (Figure 3.3A and (14)). In contrast to transfected LT
alone, infection with MCPyV virions or transfection of viral genomes robustly activates
ATM (14); additionally, LT protein levels increase over time in these settings (data not
shown). During true infection, therefore, the ATM-mediated MCPyV LTS816
phosphorylation may lead to a more robust cell-cycle arrest and apoptotic phenotype,
which may be advantageous in dispersing newly formed virions late in infection.
Alternatively, this ATM-mediated MCPyV LT S816 phosphorylation and associated
apoptotic activities may represent a host antiviral defense mechanism for eliminating
MCPyV infected cells.

It is also important to note that our study only examined LT when it is expressed
alone. Whether LT phosphorylation is altered or temporally regulated when co-expressed
with other viral proteins like sT, 57kT, or ALTO remains to be explored. Our previous
study established the DDR machinery as critical for LT mediated viral replication (49).
This study further establishes an intimate interaction between MCPyV infection and the
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host DDR, revealing how activation of a host DDR by MCPyV is then utilized by the
virus to carefully orchestrate key events in host cells. Future studies will investigate the
downstream events of MCPyV LT S816 phosphorylation by identifying the cellular
proteins that may recognize this phosphorylation event. The identification of the S816
phosphorylation site and the commercial availability of an antibody recognizing this
modification provide valuable tools for advancing our understanding of MCPyV-host
interactions.

3.5: FIGURES
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FIGURE 3.1
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FIGURE 3.1: Anti phospho-Chk1 S345 antibody cross-reacts with MCPyV LT. (A)
U2OS cells were transfected with pcDNA4C (Vector), pcDNA4C encoding Xpress
tagged MCPyV LT molecules as indicated, or pTIH encoding SV40 LT. At 36 hours post
transfection, cells were lysed and immunoblotted with the indicated antibodies. Arrows
indicate cross-reactive bands corresponding to the molecular weight of the transfected LT
molecule.

(B) U2OS cells were transfected with pEGFPC1 (Vector), or pEGFPC1

encoding MCPyV LT molecules as indicated. At 36 hours post transfection, cells were
lysed and immunoblotted with the indicated antibodies. Arrows denote cross-reactive
bands matching the molecular weight of the transfected LT molecules as indicated in (A).
Asterisks (*) indicate an additional cross-reactive band present in U2OS cells regardless
of LT expression.
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FIGURE 3.2
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FIGURE 3.2: MCPyV LT is phosphorylated at S816. (A) U2OS cells were transfected
with pcDNA4C vector (Vec) or pcDNA4C-MCPyV LT. Forty-eight hours post
transfection, cells were treated with or without Calf-intestinal alkaline phosphatase (CIP)
and analyzed by Western blot. Asterisk and arrow indicate cross-reactive bands as
described in Figure 3.1. (B) U2OS cells were transfected with pcDNA4C (Vector),
pcDNA4C-MCPyV LT1-817 (wild type LT), or pcDNA4C-MCPyV LT 1-817 S816A
(LT S816A). Forty-eight hours post transfection, cells were harvested and proteins were
analyzed by Western blot with the indicated antibodies. Asterisk and arrow indicate
cross-reactive bands as described in Figure 3.1.
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FIGURE 3.3
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FIGURE 3.3: ATM kinase phosphorylates MCPyV LT at S816. (A) U2OS cells were
transfected with pcDNA4C vector (Vec) or pcDNA4C-MCPyV LT (LT). At forty-four
hours post transfection, cells were treated with 4 µM etoposide for 4 hours or 10J UVC
light.

Cells were then harvested and analyzed by Western blot with the indicated

antibodies. Asterisk and arrow indicate cross-reactive bands as described in Figure 3.1.
(B) U2OS cells were transfected with pcDNA4C (Vec), or pcDNA4C-MCPyV LT1-817
(LT). At 44 hours post-transfection, cells were treated with DMSO, 20 µM Wortmannin,
20 µM NU6027, 1 µM NU7441, 10 µM KU55933, 10 nM AZD7762, or 10 mM Caffeine
for 6 hours. Then cells were harvested and proteins were analyzed by Western blot with
indicated antibodies. Asterisk and arrow indicate cross-reactive bands as described in
Figure 3.1.
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FIGURE 3.4
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FIGURE 3.4: ATM can bind and phosphorylate LT in vitro.

(A)

In Vitro

phosphorylation of MCPyV LT S816 by ATM. Affinity-tagged MCPyV LT or MCPyV
LT S816A was purified from 293 cells and treated with CIP. ATM and ATR proteins
were immunoprecipitated from U2OS cells which had been treated with 4 µM etoposide
for 4hr. Purified LT was then incubated with purified ATM or ATR in kinase reaction
buffer supplemented with [γ-32P] ATP.

Reactions were performed either at room

temperature (RT) or 37˚C for 30min. Reactions were separated by SDS-PAGE and then
either dried and exposed for autoradiography (top) or Western blotted for MCPyV LT
(bottom, right). Immunopurified ATM and ATR proteins were Western blotted with the
indicated antibodies (bottom, left). (B) GST-LT pull-down of ATM. U2OS nuclear
extracts were mixed with either immobilized, bacterially-derived GST or GST-LT
protein. Input nuclear extract and pull-down samples were immunoblotted with anti ATM
antibody (top). GST or GST-LT eluted from the glutathione resin was separated by SDSPAGE and stained with Coomassie Brilliant Blue (CBB) (bottom). “L” – molecular
weight ladder. “−” – empty lane.
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FIGURE 3.5
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FIGURE 3.5: C33A cells stably expressing MCPyV LT S816A form more colonies
than cells stably expressing wild-type LT. C33A cells stably expressing Cherry-LacI,
MCPyV LT or MCPyV LT S816A were seeded at 5000 cells/well in a 6 well plate. Cells
were cultured for 10 days with 0.625 µg/ml puromycin. Colonies were then fixed with
methanol and stained with methylene blue. Data shown are representative of at least
three experiments.
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FIGURE 3.6
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FIGURE 3.6: MCPyV LT induces more apoptosis than LT S816A. (A) C33A cells
were transfected with pEGFPC1 (Vector), pEGPFC1-MCPyV LT, or pEGFPC1-MCPyV
LT S816A. Twenty-four hours later, cells were stained with Annexin V-PE and DAPI.
Images are representative of at least three experiments. Bar, 10 µm. (B) The percent of
GFP positive cells with Annexin V staining was quantified from approximately 100 cells.
The mean and standard deviation (SD) was calculated from three cover slips. (C and D)
C33A (C) and HeLa (D) cells were transfected with pcDNA4C (Vector), pcDNA4CMCPyV LT, or pcDNA4C-MCPyV LT S816A. Cells were harvested at thirty hours post
transfection and cell lysates were analyzed by Western blot with the indicated antibodies.
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CHAPTER 4: MERKEL CELL POLYOMAVIRUS LT AND ST
COOPERATIVELY REGULATE THE VIRAL LATE PROMOTER

This chapter presents preliminary work elucidating how the MCPyV late
promoter is regulated by both LT and sT. I am the primary investigator and performed
all of the experiments. The NCCR reporter plasmids used in Figures 4.2 – 4.5 were
constructed by Dr. Jing Li.

A preliminary manuscript of this work is in preparation.
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4.1 SUMMARY
The work presented in Chapter 2 identified a threonine phosphorylation at T271
of MCPyV LT, but established that T271 phosphorylation was not important for viral
replication. To test whether T271 phosphorylation is important for regulation of MCPyV
promoters, transcriptional reporter constructs were generated by fusing the MCPyV
NCCR to a luciferase gene such that protein expression would be controlled by the native
early or late promoter. Preliminary results using these NCCR reporter constructs showed
that the wild-type LT could stimulate luciferase expression from the late promoter, but
only when sT was also expressed. The T271A mutant behaved identically to wild-type
LT. Interestingly, sT expression activated both Early and Late NCCR reporter constructs
to a small degree.

The dependence of LT on sT co-expression for late promoter

activation has not been previously reported in other polyomaviruses.

Follow up

experiments showed that sT’s ability to stabilize LT expression did not play a major role
in this co-operative activation phenotype. These NCCR constructs can presumably be
replicated by LT as they retain the viral Ori (see Chapter 2); therefore, increased
luciferase activity could be explained by an increase in reporter copy number. To address
this concern, I examined two phosphomutant LTs (T297A and T299A, see Chapter 2) as
well as an NCCR construct with a defective origin (Ori350, previously reported in (10)).
The T297A mutant, which exhibits robust replication from the viral Ori, stimulated
transcription just as well as wild-type LT.

The T299A LT mutant, which has an

abrogated replication phenotype, and the Ori350 NCCR mutant, which also supports very
low levels of replication, had attenuated transcriptional activation.

These results

established that MCPyV replication and/or binding of the NCCR by LT is important for
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stimulating the Late promoter. Finally, examination of the isolated Late promoter with
the rest of the NCCR, including the Ori, removed showed that LT expression actually
represses this promoter, highlighting the importance of an intact MCPyV Ori sequence
for LT-mediated stimulation of the late promoter. These results present a model where
LT expression negatively regulates the Late promoter prior to replication, and then
robustly stimulates this promoter after binding to the NCCR and initiating replication.
Interestingly, this post-replication activation by LT requires sT co-expression, revealing a
synergistic interaction not exhibited by other polyomaviruses.

4.2 INTRODUCTION
MCPyV is associated with a large majority of MCC, a rare and highly aggressive
cancer of the dermis (3,6,8,23). MCPyV-associated tumors exhibit a dependence on the
expression of the viral oncogenes LT and sT; knockdown of these proteins cause MCC
tumors to be rapidly cleared in a mouse xenograph model (32,33). MCPyV associated
cancers are therefore similar to papillomavirus associated cancers, where high expression
of oncogenic viral proteins drive tumor progression (11,12). Unlike papillomaviruses,
however, the regulation of MCPyV oncogenes has not been well studied, either in a
natural infection setting or in MCC cell lines. Similarly, MCPyV research has faced the
difficulty of finding cell lines that can efficiently propagate the virus; this difficulty
largely stems from a lack of knowledge of the cellular environment that supports
activation of either the early genes, which are necessary for replication of the viral
genome, or the late genes, which consist of the viral capsid proteins required for
generating new virions. To date, the mechanisms by which the MCPyV early and late
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genes are regulated have not been elucidated.

Increasing our knowledge of viral

transcription from both of these promoters will help us better understand MCPyV
associated oncogenesis, and may also provide clues or even tools for more efficiently
propagating fully functional virus for better studies of natural infection.

Like other polyomaviruses, MCPyV consists of a circular, doublstraded DNA
genome of about 5.3kb that is packaged into virions comprised of VP1 and VP2 capsid
proteins. The genome is bisected into an early region and a late region by a central noncoding control region (NCCR) which contains the viral origin of replication (Ori) and
promoter sequences. The early promoter regulates the expression of the Tumor antigen
locus; this open reading frame is multiply spliced into various gene products, including
LT, sT, 57kT, and ALTO. The late promoter controls the expression of the viral capsid
proteins, VP1 and VP2 (23).

The polyomavirus LT protein is a highly multifunctional protein that both
manipulates the host cell cycle and initiates replication of the viral genome. The Nterminal region of LT contains conserved binding sites for various cellular proteins,
including DnaJ heatshock protein family members and pRb, which serve to drive the host
cell into a proliferative state. The C-terminal half of the protein contains functional
domains required for initiating the replication of the viral genome, including a viral origin
binding domain (OBD) that allows LT to bind directly to the Ori within the viral NCCR,
and a helicase domain which is required for unwinding of the viral DNA (8,23). In
SV40, LT also plays a major role in regulating both the early and late promoters (140	
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148). The early promoter is activated by a variety of cellular transcription factors,
including Sp1, Sp2, and NFAT, which drive initial activation of the T-antigen locus (8486). As SV40 LT protein accumulates, it silences the early promoter and begins initiating
replication of the viral genome. After replication, the accumulated LT is then able to
efficiently stimulate the late promoter, which drives expression of the viral capsid
proteins (87,149,150). Whether MCPyV LT can similarly regulate either the early or late
viral promoters has not yet been investigated.

MCPyV sT has been shown to play an important role in both viral replication and
MCPyV associated cancers. MCPyV sT stabilizes LT expression and enhances LTmediated replication of the viral DNA (10,40). Additionally, sT uses it’s C-terminal
PP2A binding domain to manipulate the host cell in a variety of ways to induce cellular
proliferation and transformation.

Some of these functions include instigating

hyperphosphorylation of 4E-BP1 which consequently induces high levels of capdependent translation (27). MCPyV sT can also transform primary rat cells, and has been
repeatedly shown to be necessary for maintaining the transformed phenotype of many
MCPyV-associated MCC tumors (27,33,34). Interestingly, sT has been shown to inhibit
NF-κB signaling through its association with certain PP2A subunits and the NEMO
adaptor protein (38). No report has thus far demonstrated a role for sT in regulating
either of the viral promoters. In SV40 polyomavirus, sT plays a much less prominent
role in both cellular transformation and the normal viral life cycle. Additionally, it does
not regulate either of the two viral promoters, although one report showed that SV40 sT
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expression could complement a low-level of LT expression to activate the Late promoter
in a cooperative fashion (89).

We sought to better understand how the viral promoters are regulated by both LT
and sT during MCPyV infection.

Using a luciferase reporter, we investigated the

potential role(s) of both MCPyV LT and sT in the regulation of both the native MCPyV
NCCR as well as the early and late promoters in isolation.

Our results exhibit a

surprising departure from what has been known for SV40 promoter regulation. While
replication does seem to play a critical role in triggering the activation of the late
promoter, LT requires sT co-expression to robustly activate the late promoter in the
context of the native NCCR. Interestingly, reducing the binding affinity of LT for the
viral Ori, through mutation of either the viral Ori sequence itself or with LT
phosphomutants described in Chapter 2, diminishes LT’s ability to stimulate the late
promoter, even in the context of sT co-expression. Surprisingly, LT showed an inhibitory
effect on the late promoter when this sequence is isolated from the rest of the NCCR,
even in the context of sT co-expression. These results highlight the importance of the Ori
sequence for directing LT to the viral DNA, providing yet another example of MCPyV
sT’s more prominent role in the viral life cycle as compared to those of other
polyomaviruses studied thus far.

4.3 RESULTS
4.3.1 The MCPyV Late Promoter is Activated by Coexpression of Both LT and sT in the
Context of an Intact NCCR
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Our previous studies of phosphorylation modification of MCPyV LT identified
four sites: T271, T297, T299, and S816 (see Chapters 2 and 3). Of those four sites, the
functional relevance of T271 has not yet been established, despite being identified with
high confidence (see Figure 2.1). An important viral process not yet tested with the
T271A LT mutant was regulation of MCPyV transcription, an activity which in SV40 is
largely dependent on LT expression. To this end, reporter constructs were generated by
fusing the NCCR of MCPyV to a luciferase reporter plasmid such that luciferase
expression would be driven by either the Early or Late promoter regions (see Figure 4.1).
These two reporter constructs (NCCR Early and NCCR Late) were then co-expressed
with MCPyV LT and sT. LT expression had little effect on the early promoter, but had a
robust activating effect on the late promoter only in the context of sT coexpression
(Figure 4.2A and data not shown). The T271A mutant behaved identically to wild-type
LT in all cases, precluding further study of this mutant (data not shown). Interestingly,
sT expression alone was able to moderately but reproducibly activate both the early and
late constructs approximately two-fold at all time points tested with the most robust
activation seen on the late promoter when LT and sT were co-expressed (Figure 4.2A and
data not shown).

To rule out whether LT and/or sT could act as a global activator of transcription,
we tested whether these proteins could affect an interferon-sensitive response element
(ISRE). MCPyV proteins were co-transfected with a luciferase reporter under the control
of an ISRE. Cells were then treated with or without recombinant IFN-α. Luciferase
activity was greatly stimulated by IFN treatment as would be expected. Expression of the
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MCPyV proteins did not activate this protein in the absence of IFN. Interestingly,
expression of LT and especially sT severely attenuated the activation induced by IFN
treatment, showing that these proteins can actually repress this promoter (Figure 4.2B).
This finding is supported by a study showing that MCPyV sT can negatively regulate NFκB signaling (38). These results established that the activation of the viral promoters was
due to a specific interaction with MCPyV LT and sT, and not due to a more global
activation of cellular transcription.

4.3.2 Increased LT Expression Alone Does Not Account for Activation of the Late
Promoter
The observation that MCPyV LT required sT co-expression to activate the NCCR
Late reporter was surprising to us (Figure 4.2A); in SV40, LT is able to activate the late
promoter by itself following replication (87,148-150). To our knowledge, there is only
one report showing that SV40 sT could complement LT activation of the late promoter,
but only in situations where LT expression was “sub-optimal” (89). It has been well
established by our lab and others that sT expression can stabilize LT expression (data not
shown and (10,40)). We therefore asked whether LT’s robust activation of the late
promoter when sT was co-expressed was due to an increase in LT stabilization mediated
by sT. Cells were transfected with the NCCR Late reporter construct and an increasing
amount of LT expression construct either alone or with sT co-expression. Lysates were
immunoblotted for LT and sT expression to assess the extent of LT stabilization (Figure
4.3).
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Interestingly, LT was able to robustly activate the late promoter at any given
expression level, but only in the context of sT co-expression (Figure 4.3A). Western blot
analysis showed that co-expression of sT did in fact stabilize LT expression (Figure 4.3B,
compare LT expression of a given level when sT is absent or present). The expression
level of LT alone, however, did not explain the activation of the late promoter. For
example, the overall LT expression level was similar between the 2xLT/sT and 5xLT
samples; however, the late promoter was only robustly activated in the 2XLT/sT
condition (Figure 4.3B). Furthermore, the LT expression level of 5xLT is well above that
seen for 1xLT/sT, yet it is only in the latter condition that the late promoter is robustly
activated (Figure 4.3B). These observations indicate that sT expression has enhancing
activity on the late promoter independent of its ability to stabilize LT expression. It is
important to note that this activation phenotype was somewhat reduced in the 5xLT/sT
setting; it is possible that LT might saturate whatever helper function sT might have when
expressed at this level, although additional experiments will have to be performed to
more clearly define this phenomenon.

4.3.3 Replication of the NCCR Reporter Partially Contributes to Late Promoter
Activation
Polyomaviruses commonly exhibit robust late promoter activation following
replication. The NCCR reporter constructs used in this study retain an intact Ori which
would presumably be targeted by LT for replication. In addition to MCPyV LT and sT
acting as molecular switches for late promoter activation, increasing numbers of reporter
plasmid could artificially inflate the reporter signal due to an increase in reporter copy
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number. Additionally, sT’s stabilization of LT is known to stimulate LT’s ability to
replicate the viral Ori (10). The results in Figures 4.2 and 4.3 could therefore be solely
due to an increase in copy number of the NCCR reporter.

To begin addressing this question, we introduced the previously reported Ori350
mutation into the NCCR reporter construct (10,49,151). This mutation was derived from
an MCC tumor and introduces a single nucleotide substitution in pentanucleotide 7 of the
MCPyV Ori (Figure 4.1), which severely abrogates LT-mediated replication from this
Ori (10). We then used quantitative PCR to measure the amount of either wild-type or
Ori350 mutated NCCR reporter plasmids in the presence and absence of MCPyV LT and
sT after four days of expression (Figure 4.4A).

As expected, the wild-type NCCR Late reporter replicated to a high degree (about
two-fold) in the presence of both LT and sT; expression of just LT induced a modest
increase in reporter number. The Ori350 NCCR Late reporter also replicated to a small
degree when LT and sT were co-expressed, but this replication was severely abrogated
compared to the wild-type NCCR Late reporter (Figure 4.4A). Interestingly, examination
of luciferase activity in this setting shows that copy number only partially contributes to
the observed increase in luciferase activity driven by the NCCR Late reporter (Figure
4.4B).

The luciferase activity of the WT NCCR Late reporter was stimulated

approximately eight-fold when LT and sT were co-expressed (Figure 4.4B), even though
the total copy number only increased two-fold in this setting (Figure 4.4A). Additionally,
even though the Ori350 NCCR Late reporter did replicate to a small but measurable
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degree when LT and sT were co-expressed, this construct failed to exhibit luciferase
activity over vector control. A previous report showed by ChIP analysis that LT binding
to Ori350 is greatly reduced, presumably because this mutation disrupts a key LT binding
site (10). It is possible, therefore, that LT binding to the Ori is required for its ability to
activate the late promoter. These data suggest that the combined effect of LT binding to
the viral NCCR and sT expression, rather than NCCR plasmid copy number alone,
contribute to the observed increase in NCCR Late luciferase activity.

4.3.4 A Phosphomutant LT With a Defective Replication Phenotype Still Robustly
Activates the Late Promoter
In a previous chapter, I described two LT phosphomutants (T297A and T299A)
which exhibited altered replication phenotypes (see Chapter 2). The T297A mutant
exhibits enhanced replication of MCPyV Ori plasmids, likely because it can bind the Ori
with greater affinity than wild-type LT; conversely, the T299A mutant, which exhits
reduced binding to the viral Ori, fails to replicate MCPyV Ori plasmids (Figures 2.3, 2.5
and 2.6).

To further probe whether replication plays a role in activating the late

promoter, I tested these mutants for their ability to stimulate NCCR Late promoter driven
luciferase activity in the presence or absence of sT (Figure 4.5). Southern blot analysis
confirmed that the T297A mutant could replicate to a high degree, and that this activity
was greatly stimulated by co-expression of sT; T299A on the other hand failed to
replicate plasmids with or without sT co-expression (data not shown). Surprisingly, all
LT mutants behaved similarly to wild-type LT: they were all able to activate the NCCR
Late reporter, but only when co-expressed with sT. Interestingly, the activation of the
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NCCR Late reporter was slightly attenuated with the T299A mutant, which has reduced
binding affinity to the MCPyV Ori (Figure 2.6). This is in agreement with the Ori350
NCCR Late promoter reporter data presented in Figure 4.4, where reduced MCPyV LT
binding to the NCCR Late promoter reporter prevented activation of the promoter despite
a small level of observed replication (see section 4.3.3). Together, these results rules out
replication of these plasmids as a major contributing factor for the increased luciferase
activity, and suggest that LT binding to the Ori in the presence of sT expression is critical
for NCCR Late reporter activation.

4.3.5 MCPyV LT Silences the Late Promoter in the Absence of Ori Sequences
The experiments presented thus far have been in the context of a native NCCR,
which includes both promoter sequences and the viral Ori. Data presented in Figures 4.4
and 4.5 suggest that binding of the Ori sequences and/or replication in the presence of sT
may play a major role in LT’s ability to activate the late promoter. We asked how LT
and sT might act on the Late promoter when the Ori was no longer present. The isolated
Late promoter (highlighted in green in Figure 4.1) was cloned into the same luciferase
reporter vector and assessed for activation by LT and sT. sT was still able to activate the
isolated Late reporter when expressed alone; however, LT expression actually reduced
activation of the isolated Late reporter below vector control levels. Co-expression of sT
and LT showed activity similar to vector (figure 4.6A). We were surprised to see LT
show such a robust silencing effect; we therefore tested whether scaling down the dose of
LT would relieve this repression. Interestingly, LT showed a robust silencing effect at all
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doses tested; expression of sT was not able to overcome this silencing effect, although it
still activated the late promoter when expressed alone (data not shown).

4.4 DISCUSSION
Thus far, little research has been done to understand how MCPyV gene
expression is regulated. Knowledge of viral gene regulation is important not just for
understanding natural infection, but also in the case of MCPyV associated cancers, where
high expression of the viral oncogenes is necessary for tumorigenesis.

This work

represents a preliminary investigation of the regulation of the MCPyV promoters through
the lens of the viral protein products themselves. Polyomaviruses generally utilize the LT
protein as a major regulator of both early and late gene transcription (87,148-150).
MCPyV sT has also shown itself to be a critical protein involved in various MCPyV
activities (10,27,34,38,40), so both of these proteins were tested for their ability to
regulate the early and late viral promoters.

Reporter constructs were first generated utilizing the entire NCCR of MCPyV to
keep the early and late promoters close to their native configurations (Figure 4.1). An
initial look at promoter activation by both LT and sT showed that sT could surprisingly
activate both promoters at a small but reproducible level (two-fold, Figure 4.2A and data
not shown).

This was independent of time-point or promoter (data not shown).

Interestingly, expression of LT alone showed little activity, in some cases even repressing
the late promoter (Figure 4.2A, Day 3). At four days post transfection, however, LT was
able to robustly activate the late promoter, but only in the context of sT co-expression.
	
  

98	
  

This is in contrast to SV40 where LT expression alone is able to stimulate late gene
expression.

The stimulation of the viral promoters was not due to a global effect on
transcription: analysis of an interferon-sensitive response element showed that LT and
especially sT actually repressed transcription from these reporters upon interferon
stimulation (Figure 4.2B). sT’s cooperative activity with LT to activate the late promoter
could partially be explained by a dramatically increased level of LT expression when sT
is coexpressed, as sT is able to stabilize LT protein expression (40); however, higher LT
expression alone was not able to stimulate the NCCR Late promoter (Figure 4.3). Even
with a five-fold increase in transfected LT, sT was required for robust activation of the
NCCR

Late

promoter

(Figure

4.3).

The observed increase in the NCCR Late reporter luciferase activity could also be
explained by the replication of this reporter in the context of LT expression. These
reporter constructs contain the native MCPyV NCCR, which includes the viral Ori. LT
binds to the viral Ori to initiate replication (See Chapter 2) and could presumably
replicate these reporter constructs as well; the observed increase in the NCCR Late
reporter luciferase activity could be due to an increase in reporter copy number after four
days of LT expression. To address this issue, we measured the copy number of NCCR
plasmids in cells after four days with or without LT or sT expression. While a two-fold
increase in plasmid number was evident when LT and sT were co-expressed, the increase
in NCCR Late promoter activation (> 8 fold) far exceeded this increase in plasmid count
	
  

99	
  

(Figure 4.4). We also examined an NCCR with a point mutation in a LT binding site
located in the viral Ori (termed Ori350, Figure 4.1), which has previously been shown to
have reduced replication and LT binding (10,49). This mutant NCCR was still able to
replicate to a very small degree when LT and sT were co-expressed, but the NCCR Late
promoter failed to be activated from this construct (Figure 4.4). Additionally, expression
of phosphomutant LT proteins which either exhibit enhanced (T297A) or abrogated
(T299A) replication were still able to activate the NCCR Late promoter, again only in the
context of sT co-expression (Figure 4.5).

These results indicate that the promoter

activation phenomenon is not likely due solely to an increase in reporter copy number.

Interestingly, when the Ori and Early promoter are removed, LT appears to
suppress the isolated late promoter, even when sT is co-expressed (Figure 4.6). A similar
phenomenon can be noted in the NCCR construct at day 3 (Figure 4.2, Day 3 data). This
isolated Late promoter construct represents an artificial setting that demonstrates what
might happen at this promoter prior to replication. In the greater scheme of the viral life
cycle, it makes sense for the late promoter to be repressed prior to genome amplification.

Polyomaviruses have traditionally used replication as a major switch towards
activating the late promoter. The data presented here supports the notion that the viral
Ori is critical for efficient activation of the late promoter. Both an NCCR mutated with
the Ori350 LT binding site mutation and a LT mutant with decreased affinity for the viral
Ori (T299A, see Figure 2.6) showed attenuated activation of the late promoter, albeit to
different degrees. Removal of the Ori revealed LT’s ability to strongly repress the late
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promoter (Figure 4.6). These data suggest that LT binding to the Ori is required for
efficient activation of the late promoter.

The molecular mechanisms by which Ori

binding stimulates Late promoter activation, and only in the context of sT co-expression,
are not clear. It is possible that replication of the viral genome causes physical changes
to the viral chromatin structure that allow access to cellular transcription factors.
MCPyV LT is known to recruit the host cellular chromatin factor Brd4 to viral replication
foci; it is possible that Brd4 not only recruits RFC1 to help stimulate replication, but also
occupies newly formed viral genomes to then recruit P-TEFb and stimulate transcription
(50). Additionally, other factors left over after replication, such as PCNA, may signal or
recruit transcription factors, or interact with LT or sT in some way as to stimulate late
promoter activation. All of these factors represent exciting areas of research that should
be pursued to increase our understanding of the activation of late gene expression and
virion assembly. Finally, it is interesting to note that sT was only able to co-activate the
late promoter in the context of an intact NCCR: although sT alone was able to activate
the Isolated Late reporter modestly, it was unable to counteract LT’s repressive activity
(Figure 4.6). This may indicate that sT activity is somehow tied to LT binding to the Ori,
although the molecular mechanisms of this interaction remain largely speculative at this
point.

The studies presented in this chapter focus exclusively on the regulation of the
late promoter. The early promoter was similarly studied, both in the context of the native
NCCR, as well as in isolation. Results from these experiments were much more variable
and inconsistent, although in general sT expression was able to stimulate both the early
	
  

101	
  

and late promoters at almost all time points (data not shown). This stimulation was
consistently modest (two-fold) but extremely reproducible. It is likely that sT exhibits
some activity that somehow primes the host cell for transcription from the viral genome,
likely through its PP2A binding activity. It would be interesting to test whether PP2A
binding mutants show differential activity on either promoter, or on sT’s ability to coactivate the late promoter with LT.

Ultimately, without a robust infection system, the data presented here represent a
somewhat artificial look at MCPyV transcription; a true infection system with a natural
host cell will greatly advance our understanding of MCPyV virology. It would similarly
be interesting to examine the MCPyV gene expression dynamics of both the early and
late promoters in the context of Merkel cell infection, as this may provide clues towards
understanding the early events of oncogenesis. Unfortunately, cells lines of either human
Merkel cells or even MCPyV-negative MCC cells do not currently exist, further
hampering progress towards better understanding this important tumor virus.

Even with these limitations, however, this preliminary study sheds some light on
MCPyV late promoter activation, and once again highlights how MCPyV is distinct from
other polyomaviruses. Whereas SV40 LT is largely sufficient on its own to regulate viral
gene expression and transform infected cells, MCPyV has shown a greater dependence
on sT function for both tumorigenesis and, in this study, promoter activation. Ultimately,
a better understanding of viral gene expression, both in the context of natural infection
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and in Merkel cells, will help advance our understanding of MCPyV pathogenesis and
cancer progression.

4.5 FIGURES
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FIGURE 4.1

FIGURE 4.1: The MCPyV Non-coding Regulatory Region. The regulatory region of
the MCPyV R17b isolate was used to generate the NCCR Early and NCCR Late
reporters. Perfect LT binding sites (GAGGC pentanucleotides) are highlighted in red,
while inverted complementary sequences (CTCCG) are highlighted in blue. Imperfect
repeats are noted in orange and light blue. The Ori350 mutant is a CA substitution in
pentanucleotide 7 which abrogates replication (asterisk, (10)). The location of the early
and late regions of MCPyV are noted. The isolated Late Promoter used in this study is
highlighted in green.
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FIGURE 4.2

	
  

105	
  

FIGURE 4.2: MCPyV LT and sT cooperate within the NCCR to activate the late
promoter. (A) 293 cells were co-transfected with NCCR Late Luciferase Reporter and
various combinations of MCPyV LT and sT expression constructs. Cells were collected
at the indicated times post transfection. Luciferase activity was normalized to protein
content. Graphs show the mean of a triplicate transfection; error bars represent the
standard deviation from the mean.

Data are representative of three independent

experiments. (B) 293 cells were co-transfected with an Interferon-Sensitive Response
Element reporter plasmid and the indicated MCPyV gene construct. Twenty-four hours
post-transfection, cells were stimulated with recombinant IFN-α or PBS. Forty-eight
hours post-transfection, cells were collected.

Luciferase activity was normalized to

protein content. Graphs show the mean of a triplicate transfection; error bars represent the
standard deviation from the mean.

Data are representative of three independent

experiments.

	
  

106	
  

FIGURE 4.3

FIGURE 4.3: LT protein level alone does not explain late promoter activation. 293
cells were co-transfected with the NCCR Late Luciferase reporter and increasing
amounts of LT expression plasmid with or without a constant amount of sT expression
plasmid. Cells were collected four days post-transfection. (A) Luciferase activity was
normalized to protein content. Graphs show the mean of a triplicate transfection; error
bars represent the standard deviation from the mean. (B) Lysates were separated by
SDS-PAGE and immunoblotted for the indicated proteins. Data are representative of
three independent experiments.
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FIGURE 4.4

FIGURE 4.4: An intact origin of replication is required for late promoter activation.
(A) 293 cells were transfected with the indicated MCPyV proteins and either WT NCCR
Late or the replication-defective Ori350 NCCR Late Luciferase reporter. Wholegenomic DNA was extracted from cells collected four days post-transfection. NCCR
plasmids were measured by qPCR (calculated against a standard curve, depicted on the
right, with an R2 value of 0.99988) and normalized to GAPDH. (B) 293 cells were
transfected as in (A) and collected four days-post transfection. Luciferase activity was
normalized against protein content. Graphs show the mean of a triplicate transfection;
error bars represent the standard deviation from the mean. Data are representative of
three independent experiments.
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FIGURE 4.5

FIGURE 4.5: A MCPyV LT replication-defective mutant can still activate the late
promoter. 293 cells were co-transfected with the NCCR Late Luciferase reporter and the
indicated LT expression plasmid with or without sT expression plasmid. Cells were
collected four days post-transfection. (A) Luciferase activity was normalized protein
content. Graphs show the mean of a triplicate transfection; error bars represent the
standard deviation from the mean. (B) Lysates were separated by SDS-PAGE and
immunoblotted for the indicated proteins. Data are representative of three independent
experiments.
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FIGURE 4.6

FIGURE 4.6: MCPyV LT represses the late promoter when the viral origin is
absent. 293 cells were transfected with the MCPyV isolated Late Luciferase reporter
with or without sT co-expression. Two-days post-transfection, cells were collected, and
luciferase activity was normalized to protein concentration. Graphs show the mean of a
triplicate transfection; error bars represent the standard deviation from the mean. Data are
representative of four independent experiments.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.1: Regulation of MCPyV LT Function by Phosphorylation
5.1.1: Regulation of Protein Function by Phosphorylation
A majority of my thesis work has centered around a fundamental question: how
are the myriad of functions of a complex viral protein like MCPyV LT regulated to allow
for the exquisitely coordinated progression of viral infection?

The LT protein of

polyomaviruses is involved in almost every facet of the viral life cycle, including
manipulating the host cell cycle to favor proliferation, initiating replication of the viral
genome, and (usually) controlling the expression of early and late genes such that Tantigens are expressed first to manipulate the cell, and capsid proteins are expressed only
when it is convenient to produce new virions. Understanding how LT protein function is
regulated is the heart of elucidating how polyomaviruses coordinate their life cycle in
host cells.

Polyomavirus LT proteins were readily identified as highly phosphorylated, and
the functional relevance for many of these modifications remain a mystery even for
SV40, arguably one of the best studied viruses in the world. Phosphorylation is a
versatile post-translational modification, as it is readily added and removed from
substrates by kinases and phosphatases, respectively, allowing for a dynamic regulation
of protein function in response to an ever changing cellular environment. In addition to
acting as a molecular mark whose presence or absence can be recognized by other
proteins, the negative charge inherent to the phosphate moiety can be utilized to alter
protein structure or interaction with other proteins.
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The work presented here represents a first look at how phosphorylation regulates
MCPyV LT function, and provides many avenues of research worth pursuing to better
understand the basic life cycle of this important tumor virus.

5.1.2: Regulation of MCPyV Replication by Phosphorylation of LT T297 and T299
The work presented in Chapter 2 identified three threonine phosphorylation sites
on MCPyV LT (Figure 2.1). Ultimately, two of them (T297 and T299) proved to be
important regulators of LT-mediated replication. Identification of T299 as a phospho-site
was encouraging to me because of its homology to a well-described regulatory threonine
in SV40 LT, providing confidence in the validity of my mass spectrometry data. Its
homology to T124 in SV40 LT naturally led me to ask whether this mutant abrogates
replication; this hypothesis ultimately proved to be correct (Figures 2.3 and 2.5). To my
surprise, T297 was identified as being equally important, if in an opposite fashion; the
T297A mutant actually showed enhanced replication, well over that seen for wild-type
LT (Figures 2.3 and 2.5). This finding was completely unexpected to me, and led me to
generate models to better understand the underlying molecular mechanisms.

Modeling of the LT OBD suggested that T297 faces the LT/DNA interaction
interface (Figure 2.2); electrostatic theory would predict that a phosphate moiety at this
site would be repelled by the negatively charged phosphate backbone of DNA; therefore,
the alanine mutant would have this repulsive interaction abrogated. In line with this
reasoning, electromobility shift assays showed that the T297A mutant had enhanced
affinity for the viral Ori, while the T299A mutant showed reduced Ori binding. To test
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the hypothesis that electrostatic interactions drive T297’s regulation of replication, I
could test whether a T297D or T297E mutant evidence reduced binding. The functional
consequence of T299 phosphorylation is not as clear. In the homologous site on SV40
LT, the major outcome of phosphorylation at this site is stimulation of interactions
between adjacent hexameric LT complexes assembled at the viral origin. Using an
elegant series of DNA probes, Barbaro and colleagues were able to show this doublehexamer interaction and its dependence on T124 phosphorylation in SV40 by splitting the
SV40 Ori in half, retaining two of the four LT binding sites in both probes (73). The
SV40 Ori is largely symmetrical, with opposing pairs of GAGGC repeats for recruiting
LT flanked by A/T rich or palindromic sequences (see Figure 1.2). In contrast, the
MCPyV Ori has an asymmetric organization, with as many as ten potential LT binding
sites separated by a large A/T rich tract; a second A/T rich track caps the late end of the
Ori (10,28).

Due to this unique nature of the MCPyV origin, as well as technical

difficulties with my own hands, I was unable to recapitulate this finding in MCPyV LT,
although I would predict that T299 phosphorylation behaves very similarly to T124 in
SV40. A more rigorous demonstration of this remains to be seen.

These data suggest a model where phosphorylation at T299 enhances LTmediated replication, presumably by stimulating hexamer-hexamer interactions, while
T297 phosphorylation would act as a brake to prevent unscheduled genome replication by
reducing the affinity of LT for the viral Ori. Unfortunately it is currently impossible to
begin probing the temporal dynamics of phosphorylation at these sites during the viral
life cycle – we lack both the specific antibodies required for assessing phosphorylation at
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these sites, and a relevant cell culture system that recapitulates a “natural infection.”
Additionally, we have little clues as to the kinase(s) and potentially phosphatase(s)
involved in adding or removing phosphates from these two critical threonines.
Phosphorylation of T124 in SV40 LT is mediated by a cyclin dependent kinase in vitro
(71); while this has not been definitively proven in vivo, the virus would likely want to
initiate replication only when the host cell has transitioned into S-phase, when the DNA
synthesis machinery has been primed.

Phosphorylation of T297 could follow a myriad of routes, depending on whether
it functions to prevent premature initiation of replication, to put a brake on replication
after amplification of the viral genomes, or both. T297 lies within a region of LT which
in SV40 is commonly found phosphorylated early in infection, albeit at serine residues;
these phosphorylation marks similarly reduce SV40 LT’s capacity to replicate the viral
genome (77,79,93).

Interestingly, it is believed that PP2A phosphatases might be

involved in removing these marks as infection transitions to amplification of the viral
genome (76,78). Given sT’s ability to interact with PP2A proteins, it is interesting to
speculate whether an additional layer of regulation of LT phosphorylation exists with this
accessory protein. Thus far, MCPyV sT has proven to be a major player in the MCPyV
life cycle, quite contrary to SV40 in which it plays a largely supporting role; it would not
be surprising, therefore, to discover that sT plays a major role in regulating LT-mediated
transcription not just by stabilizing the LT protein but also by regulating the
dephosphorylation of key inhibitory phosphates, like T297 phosphorylation.
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5.1.3: Phosphorylation of MCPyV LT by ATM Kinase at S816
The interaction between DNA viruses and the host DDR has been an emerging
field of interest in the past decade. That DNA viruses must contend with the DDR
machinery – either to subvert unwanted activities or co-opt these pathways for their own
replication – has now become a major theme in DNA virology. In the case of MCPyV,
our lab showed that LT expression alone induces activation of a host DDR response (14).
Our more recent work demonstrated that components of the DDR machinery are actively
recruited to viral replication centers, and disruption of this machinery had a negative
impact on viral replication (49). It is clear that MCPyV interacts with the host DDR, but
precisely how, and for what reason, has remained an open question.

Our identification of a cross-reactive activity with an antibody specific for serine
345 phosphorylation of a key DDR protein, Chk1, leading to the discovery yet another
phosphorylation site on LT: serine 816. We immediately hypothesized that some DDR
kinase might be responsible for this phosphorylation, as the epitope recognized by the
cross-reactive antibody represented a classic “S/T-Q” site recognized by both ATM and
ATR kinases, and we already knew that the DDR machinery was activated by LT and
recruited to viral replication centers, as already outline above. Using in vitro techniques,
we were able to show that, indeed, ATM kinase is able to interact with LT and mediate
phosphorylation at S816 (Figure 3.2, 3.3 and 3.4). We then attempted to uncover the
functional relevance of MCPyV LT phosphorylation at S816. MCPyV LT expression has
a well-documented growth-inhibitory property that had been localized by our lab and
others to the C-terminal half of the protein (13,14).
	
  

115	
  

We therefore asked whether

phosphorylation at S816 was involved in this growth inhibition. Clonogenic assays and
screens of molecular markers of apoptosis seem to lend some support for this hypothesis,
but the effects are modest, at best (Figure 3.5 and 3.6). It is unclear whether other
MCPyV LT function(s) are regulated by the phosphorylation of S816; even if its only
function was indeed to arrest the host cell, it is not clear whether this activity is a strategy
employed by MCPyV to maintain the cell in a pseudo-S-phase/G2 state, or if this
represents a host anti-viral strategy to eliminate virally infected cells. More rigorous
exploration of other potential functions of S816 phosphorylation is necessary to better
understand how MCPyV might subvert – or be victim to – the host DDR machinery.

It is interesting to note that 57kT retains the C-terminal 100 amino acids of LT,
and presumably shares this phosphorylation site. Although we currently do not have
much information about 57kT’s function during infection, it would be interesting to test
whether this protein is indeed phosphorylated at the same site, and whether this has a
more obvious phenotype on this smaller tumor antigen.

5.1.4: Uncovering the Function of MCPyV LT T271 Phosphorylation
One of the more fascinating aspects of MCPyV LT is the presence of a 200 amino
acid stretch flanking the “LXCXE” pRb binding site, which is unique to MCPyV LT and
does not exist in any other polyomavirus LT discovered thus far. This region has been
termed the MUR and has generated a lot of curiosity and interest, although currently no
functional data have surfaced apart from one report showing a vacuolar sorting protein
binds LT in this region (24). MCPyV has thus far proven to behave very differently from
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its more well studied SV40 counterpart, and it has been thought that understanding the
function of the MUR may help us better understand what unique functions MCPyV LT
has acquired.

Of particular interest to me was the identification of T271 phosphorylation. Of
the three sites identified in Chapter 2, the phosphorylated T271 peptide was most
frequently captured in both the standard and titanium oxide purification schemes,
providing high confidence that this site is likely phosphorylated during LT expression
(Figure 2.1). Despite this, I have been unable to find any functional phenotype for a
T271A mutant in relation to transcription, replication, or cell cycle control. Of all the
work presented here, this phosphorylation site remains a major area of potential new
research and represents a key clue into uncovering novel functions acquired by the
MCPyV LT unique region. It is again interesting to note that 57kT retains the amino acid
sequence for this phosphorylation site, and therefore it may be more relevant in that
protein than in full length LT.

5.2: Regulation of Viral Transcription
I began my work on viral transcription primarily as a means of screening the
T271A LT mutant for a potential phenotype. To my surprise, contrary to what had been
reported for SV40, MCPyV LT was unable to activate the late promoter on its own in the
context of the native NCCR; it required sT co-expression (Figure 4.2). I also uncovered a
dependence on viral replication and/or binding of LT to the MCPyV Ori for robust
activation of the late promoter (Figure 4.4 and 4.5), although this phenomenon has
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already been described for polyomaviruses (146,147). Unfortunately, difficulty in getting
consistent results with the early promoter constructs, coupled with the fact that MCPyV
LT can negatively regulate a number of control reporter constructs used in various
reporter assays, has made progress in studying transcription preliminary at best.
Developing a more robust transcription assay system with better transfection controls will
help solidify the data I have already generated and hopefully lead to new discoveries with
the early promoter as well.

A better understanding of the regulation of the early and late promoter is critical
for advancing our knowledge of both MCPyV natural infection and its associated
oncogenesis. Our current lack of a viable cell-culture model for propagating virus is due,
in part, to a lack of a tissue culture system for stimulation of the early and late promoters.
A greater understanding of the requirements for efficient activation of these promoters
can help us identify a more natural host cell, or engineer new tools to make propagation
and infection with virions much less laborious. Additionally, understanding how the
early promoter in particular is regulated will be key for understanding how this regulation
is altered in MCC, in which sT and LT can both be expressed and are often required for
maintaining the cancer phenotype (9,33,34).

5.3: Current Obstacles in Basic MCPyV Research
The major obstacle, by far, facing the field is the lack of a viable cell culture
system for propagating virus. Any research into the basic life cycle of MCPyV thus far
has largely been done using overexpression of viral proteins in isolation or sometimes in
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combination. Re-ligated genomes or molecular clones of MCPyV have offered more
relevant systems for exploring viral infection, but the delivery systems for these genomes
are still artificial. Once a viable cell culture model has been established, much of the
work that has been performed to understand MCPyV replication, transcription, and cell
cycle manipulation will have to be repeated. A viable and physiologically relevant
system might also allow us to finally uncover the function of a variety of unique aspects
of MCPyV that have thus far eluded us, such as the function of the MCPyV LT MUR or
the contribution of 57kT.

5.4: Concluding Remarks
My thesis work has explored basic aspects of early MCPyV activities, focusing on
the LT protein. In addition to tying key post-translational modifications of LT to its
various functions in cells, my work also highlights how MCPyV is unique among
polyomaviruses in its greater dependence on sT; further exploration of how the
phosphorylation sites I identified are regulated will likely uncover even more unique
ways in which MCPyV has adapted to its host. The eventual development of a viable and
physiologically relevant cell culture system will pave the wave to an explosion of new
knowledge for this critically important human tumor virus.
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CHAPTER 6: MATERIALS AND METHODS

6.1: Cell Lines, Cell Culture and Transfection
HEK 293, HEK 293T, HeLa and C33A cell lines were maintained in Dulbecco’s
Modified Eagle Medium (DMEM; Invitrogen) supplemented with 10% fetal bovine
serum (Hyclone). HEK 293TT cells, a gift from Chris Buck (NCI), were generated by
stably transfecting 293T cells with an SV40 LT expression plasmid, pTIH, which also
contains a Hygromycin resistance cassette (152).

293TT cells were maintained in

DMEM supplemented with 10% fetal bovine serum and 250 µg/mL Hygromycin B
(Clontech).

U2OS cells were maintained in McCoy’s 5A medium (Invitrogen)

containing 10% fetal bovine serum (Hyclone, Logan, UT, USA). FuGENE6 transfection
reagent (Roche Applied Science), or Lipofectamine 2000 (Invitrogen) reagents were used
to transfect 293TT, U2OS, C33A, or HeLa cells per the manufacturer’s instructions in the
work presented in Chapter 3. HEK 293, 293T and C33A cells were transfected using the
calcium phosphate method as described previously (50).

6.2: Recombinant Plasmids
Construction of the pcDNA4c-MCPyV LT, pcDNA-MCPyV LT 1-211,
pcDNA4C-MCPyV LT 212-440, pcDNA4C-MCPyV LT 1-440, pcDNA4C-MCPyV LT
212-817, pcDNA4C-MCPyV LT 1-817, pEGFPC1-MCPyV LT 1-440, pEGFPC1MCPyV LT 441-817, pEGFPC1-MCPyV LT 1-817, pcDNA4C-IIT-MCPyV LT 1-817,
pLPCX-Cherry-LacI, pLPCX-MCPyV LT 1-817, pGEX-MCPyV LT and pcDNA4cMCPyV Ori plasmids have been described previously (14,50). For the phospho-mutant
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constructs T271A, T297A and T299A, Quik-Change Site-Directed Mutagenesis
(Stratagene) was performed. Briefly, synthetic oligonucleotides containing the desired
mutation were annealed with denatured template plasmid pcDNA4c-MCPyV LT and
extended

with

Pfu

Turbo

polymerase

(Agilent

Technologies)

following

the

manufacturer’s instructions. Unmutated plasmid DNA templates were removed by DpnI
digestion, and the remaining DNA was used to transform DH5α competent cells. To
generate IIT affinity-tagged constructs, a DNA sequence encoding two IgG binding
domains of Staphylococcus aureus protein A and a TEV protease cleavage site was fused
in frame to the N terminus of MCPyV LT constructs using the KpnI site of the
pcDNA4c-MCPyV LT expression construct.

The NCCR reporter constructs were generated by PCR amplifying the NCCR of
the pMoHF construct (derived from the MCPyV R17b isolate, a gift from Chris Buck,
NCI) and subcloning into the KpnI site of pGL4-Basic (Promega). The primers used
were (MCPyV NCCR 1: 5’ – CGGGGTACCTGAAAAATAAATAAGG – 3’; MCPyV
NCCR 2: 5’ – CGGGGTACCTTGTCTATATGCAGAAG – 3’). The NCCR Ori350
constructs were generated by introducing the CA mutation in pentanucleotide 7 of the
MCPyV Ori sequence of pGL4-NCCR constructs using QuikChange Site-Directed
mutagenesis (Stratagene). The Isolated Late Reporter was generated by PCR amplifying
the late promoter of pMoHF and cloning it into the KpnI and XhoI sites of pGL4-Basic.
The primers used were Isolated Late For: 5’ – TAGGTACCAGGCAGCCAAGTTGTGG
– 3’ and Isolated Late Rev: 5’ – TACTCGAGTGAAAAATAAATAAGG – 3’.
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The pELU-ISRE reporter plasmid for assessing Type 1 Interferon signaling was a
gift from Dr. Susan Weiss, University of Pennsylvania. The pTIH construct expressing
SV40 LT, as well as the expression constructs for MCPyV sT, pMono-Blast, pWM,
pMtBs and pMtW, were gifts from Chris Buck, NCI. All constructs were confirmed by
DNA sequencing.

6.3: Antibodies and Chemicals
The following antibodies were used for immunoflourescent staining: mouse antiXpress (R910-25, Invitrogen), rabbit anti-RFC1 (H-300, Santa Cruz), rabbit anti-RPA70
(2267, Cell Signaling), Alexa Fluor 594 goat anti-rabbit IgG (A11012, Invitrogen), and
Alexa Fluor 488 goat anti-mouse IgG (A11001, Invitrogen). The polyclonal rabbit antiBrd4CA recognizes aa 1313–1362 (83). The rabbit polyclonal antiserum raised against
MCPyV VP1 was a gift from Chris Buck, NCI (17).

Antibodies used for western blotting include: mouse anti-MCPyV LT (sc-136172,
CM2B4, Santa Cruz), mouse 2t2 (recognizes the common N-terminal domain of MCPyV
sT and LT; gift from Chris Buck, NCI), mouse anti-glyceraldehyde 3-phosphatedehydrogenase (GAPDH) (G8140-01, US Biological), mouse anti-Xpress (R910-25,
Invitrogen), rabbit anti-phosphorylated ATM Ser1981 (ab-81292, Abcam), rabbit antiATM (2873s, Cell Signaling), rabbit anti-ATR (ab-2905, Abcam), mouse anti-PCNA (ab2426, Abcam), rabbit anti-phosphorylated Chk1 Ser345 (2348s, Cell Signaling), mouse
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anti-actin (MAB 1501M, Chemicon), HRP conjugated goat anti-mouse (7076s, Cell
Signaling), and HRP conjugated goat anti-rabbit (7074s, Cell Signaling).

Mouse anti-ATM (2873S, Cell Signaling), rabbit anti-ATR (ab-2905, Abcam),
normal rabbit IgG (12-370, Millipore), and normal mouse IgG (12-371, Millipore) were
used for immunoprecipitations.

Etoposide, wortmannin, NU 6027, caffeine and puromycin were purchased from
Sigma. NU 7441 was purchased from TOCRIS Bioscience. KU 55933 was purchased
from EMD Millipore. AZD 7762 was purchased from Selleck Chemicals. Calf-intestinal
alkaline phosphatase (CIP) was purchased from New England Biolabs. Annexin V-PE
was purchased from BioVision. AcTEV protease was obtained from Invitrogen. Western
Lightning Plus-ECL solution was purchased from Perkin Elmer (NEL).

6.4: Sample Preparation for Mass Spectrometry Analysis
HEK 293 cells were transfected with IIT-tagged pcDNA4c-MCPyV LT using the
calcium phosphate method (50). Forty-eight hours post-transfection, nuclear extracts
were prepared. Briefly, cells were resuspended in Buffer A supplemented with
phosphatase inhibitors (10mM HEPES [pH 7.9], 10mM KCl, 0.1mM EDTA, 30mM NaF,
1mM Na3VO4, 40mM β-glycerophosphate, 0.2 mM PMSF and protease inhibitors). Cells
were swollen on ice for 10 min before NP-40 was added to a final concentration of 6%
and then vortexed for 10 sec. Nuclei were pelleted by centrifugation at 1200g at 4°C for 5
min. Nuclei were resuspended in Buffer B supplemented with phosphatase inhibitors
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(20mM HEPES [pH 7.9], 400mM NaCl, 1mM EDTA, 30mM NaF, 1mM Na3VO4,
40mM β-glycerophosphate, 0.2mM PMSF and protease inhibitors) and lysed by passing
through a 22-gauge needle 10 times. Lysates were incubuated at 4°C for 1 hr and clarified
at 20,000g at 4°C for 15 min. The supernatant was then immunopurified with IgGSepharose 6 Fast Flow beads (GE Healthcare, Pittsburgh, PA, USA), pre-blocked with
1% BSA, for 2 hr at 4°C. Bound immune complexes were washed twice with IP wash
buffer with phosphatase inhibitors (10mM Tris-HCl [pH 8.0], 150mM NaCl, 0.1% NP40, 30mM NaF, 1mM Na3VO4, and 40mM β-glycerophosphate), once with IP wash
buffer without phosphatase inhibitors, and finally once with cleavage buffer (10mM TrisHCl [pH 8.0], 150mM NaCl, 0.1% NP-40, 0.5mM EDTA, 0.5mM EGTA, and 1mM
DTT). Bound proteins were then cleaved with TEV protease (Invitrogen) in cleavage
buffer for 2 hr at room temperature. Beads were spun down and the supernatant was
boiled in sample buffer and resolved by SDS-PAGE. The gel was stained with Coomassie
Brilliant blue. The band corresponding to MCPyV LT was excised and analyzed by mass
spectrometry.

6.5: Mass Spectrometry Analysis
The mass spectrometry analysis was provided by the Proteomics Core Facility,
University of Pennsylvania. Protein samples were digested with trypsin as described by
Strader et al. (153). Digested peptides were then purified by liquid chromatography using
standard purification techniques or with a titanium oxide column (GE Healthcare
Biosciences, Pittsburgh, PA, USA). Peptides were analyzed by nanoLC/MS/MS with a
LTQ Mass Spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with a nano
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LC-2D HPLC system (Eksigent, Framingham, MA, USA). The data were analyzed with
Sequest and Scaffold software.

6.6: Sequence Alignment of Polyomavirus LT Proteins
Clone Manager 9 software was used to align the amino acid sequences of various
polyomavirus LT proteins. Amino acid sequences were aligned using the Mult-Way view
and BLOSUM 62 scoring matrix. Polyomavirus LT sequences and their NCBI accession
numbers are as follows: Merkel Cell Polyomavirus LT, R17a isolate (HM011555.1);
Murine Polyomavirus LT (NC_001515.1); African Green Monkey Polyomavirus LT
(NC_004763.2); WU Polyomavirus LT (NC_009539.1); KI Polyomavirus LT
(NC_009238.1); BK Polyomavirus LT (NC_001538.1); JC Polyomavirus LT
(NC_001699.1); SV40 LT (NC_001669.1).

6.7: Phyre2 Modeling of MCPyV LT Fragments
We modeled MCPyV LT amino acids 290–433 using Phyre2 software’s intensive
mode (154). The PDB file was then visualized using PyMOL software (155). The model
was oriented using the origin binding domain crystal structure reported by Harrison and
colleagues as a reference (28).

6.8: Immunoflourescent (IF) Staining
Cells were fixed with 3% paraformaldehyde in PBS for 20 min at 4 °C. Cells
were incubated in blocking/permeabilization buffer (0.5% Triton X-100 and 3% BSA in
PBS) for 10 min at room temperature and stained with specific primary antibodies (as
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described in the figure legends) at room temperature for 60 min. After incubation, the
cells were washed three times with blocking/permeabilization buffer and incubated with
Alexa Fluor 594 goat anti-rabbit IgG and 488 goat anti-mouse IgG (Invitrogen,
Molecular Probes, Ashburn, VA, USA) for an additional 60 min. After incubation with
the secondary antibodies, cells were counterstained with DAPI (4',6'-diamidino-2phenylindol) and examined with an Olympus IX81 inverted fluorescence microscope.

6.9: Microscopy and Image Analysis
All immunofluorescent images were collected using an inverted fluorescence
microscope (Olympus IX81) connected to a high-resolution charge-coupled device
camera (QImaging, FAST1394). Images were analyzed and presented using SlideBook
5.0 software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). The scale bars
were added using ImageJ software.

6.10: Southern Blotting
Replication assays were performed as described previously (49). Briefly, MCPyV
LT constructs were transfected into C33A cells using the calcium phosphate method (50).
Forty-eight hours post-transfection, whole genomic DNA was extracted. Genomic DNA
(15 µg) was digested with BamHI, treated with or without DpnI at 37 °C overnight, and
separated on a 0.7% agarose gel. DNA was transferred to a Hybond-N+ nitrocellulose
membrane (Amersham, Piscataway, NJ, USA) and hybridized with a pcDNA4c-MCPyV
Ori probe labeled with [α-32P] dCTP using Prime-It II random primer labeling kit
(Agilent Technologies) per the manufacturer’s instructions. The results were analyzed
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using a Phosphorimager (Typhoon 9400; GE Healthcare).

6.11: Western Blotting
For the work presented in chapter 2, cells were lysed in hypertonic lysis buffer
(10mM HEPES [pH 7.9], 500mM NaCl, 3mM MgCl2, 1mM dithiothreitol, 1mM
phenylmethylsulfonyl fluoride, and protease inhibitors) by passage through a 22-gauge
needle 10 times. After a 20-min incubation on ice, the soluble and insoluble fractions
were separated by centrifugation at 5,000rpm for 10 min at 4°C. The supernatants (20 µg)
were resolved on a SDS-PAGE gel and transferred to PVDF membrane. Membranes
were blocked in 5% PBST-milk (5% w/v milk, 0.1% Tween in Phosphate-buffered
Saline, [PBS]) for 1 hr at room temperature and incubated in PBST-milk containing
primary antibodies at room temperature for 1 hr. After washing three times with PBST,
membranes were then incubated with HRP-conjugated secondary antibodies in PBSTmilk for 1 hr at room temperature. Western blots were developed using ECL solution and
images were captured using a Fuji imaging system.

For immunoblotting with phosphospecific antibodies in chapter 3, cells were
collected thirty-six hours post transfection in lysis buffer (10mM HEPES [pH 7.9],
300mM NaCl, 3mM MgCl2, 1mM DTT, 1mM PMSF, 3mM sodium butyrate, 1mM
PMSF, 1mM NaF, 100µM Na3VO4, supplemented with protease inhibitor cocktails
(Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)) and lysed by passing
through a 26-gauge needle 10 times. After a 20 min incubation on ice with occasional
vortexing, the soluble and insoluble fractions were separated by centrifugation at 5,000
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rpm for 5 min at 4°C. The supernatant (20µg) was resolved by SDS-PAGE. Phosphatase
inhibitors (1 mM NaF and 100 µM Na3VO4) were added to electrophoresis buffer and
transfer buffer. Membranes were blocked in 5% TBST-milk (5% w/v milk, 0.1% Tween
in Tris-Buffered Saline [TBS]) for 1 hour at room temperature and incubated in TBSTmilk containing primary antibodies at 4°C overnight. For anti-phospho protein
antibodies, TBST-BSA was used instead of TBST-milk. Membranes were then incubated
with HRP conjugated secondary antibodies in TBST-milk for 1 hour at room
temperature.

For immunoblots in Chapter 4, lysates generated for the luciferase assay using the
Reporter Lysis system (Promega) were separated (25µL lysate) by SDS-PAGE and
blotted with the antibodies indicated in the figure legends.

Western blots were developed using ECL solution and images were captured
using a Fuji imaging system.

6.12: Affinity Purification of MCPyV LT
HEK 293 cells were transfected with constructs expressing IIT-tagged MCPyV
LT (wild-type or mutant) using the calcium phosphate method. Forty-eight hours posttransfection, nuclear extracts were prepared. Briefly, cells were resuspended in Buffer A
(10mM HEPES [pH 7.9], 10mM KCl, 0.1mM EDTA, 0.2mM PMSF, and protease
inhibitors). Cells were swollen on ice for 10 min before NP-40 was added to a final
concentration of 6% and then vortexed for 10 sec. Nuclei were pelleted by centrifugation
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at 1200g at 4°C for 5 min. Nuclei were resuspended in Buffer B (20mM HEPE [pH 7.9],
400mM NaCl, 20% glycerol, 1mM EDTA, 0.2mM PMSF and protease inhibitors) and
lysed by passing through a 22-gauge needle 10 times. Lysates were clarified at 20,000g at
4°C for 15 min. The supernatant was then immunopurified with IgG-Sepharose 6 Fast
Flow beads (GE Healthcare) pre-blocked with 1% BSA for 2 hr at 4°C. Bound immune
complexes were washed three times with IP 150 buffer (10mM Tris-HCl [pH 8.0],
150mM NaCl, 0.1% NP-40) and once with TEV cleavage buffer (50mM Tris-HCl [pH
8.0], 6% glycerol, 0.5mM EDTA, 0.5mM DTT, 1mM PMSF). Bound proteins were then
cleaved with TEV protease (Invitrogen) in TEV cleavage buffer, overnight at 4°C. The
beads were spun down and the supernatant collected for further biochemical analysis.

6.13: Electromobility Shift Assays (EMSA)
The EMSA probe was generated by PCR amplifying a portion of pcDNA4cMCPyV Ori (Forward Primer: TTG GCA GAG GCT TGG GGC TCC, Reverse Primer:
GCG GAA TTC TAA GCC TCT TAA GCC TC). The PCR product was purified using a
Qiagen PCR Purification Kit (Cat# 28104) following the manufacturer’s instructions. The
purified probe (100 ng) was then 5' labeled with [32P-γ] ATP with T4 Polynucleotide
Kinase (New England Biolabs, Ipswich, MA, USA) following the manufacturer’s
instructions. The labeled probe was then diluted 1:50 before being used in the EMSA.

Binding reactions (20 µL) were assembled on ice. Various amounts of affinity
purified MCPyV LT was mixed with 40 fmol labeled probe in binding buffer (30mM
Tris-HCl [pH 8.0], 10% glycerol, 0.5µg BSA, 10ng poly d(I-C), 40ng Sonicated Salmon
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Sperm DNA, 5mM AMP-PNP, 1mM DTT, and 1mM PMSF). Reactions were incubated
at room temperature for 25 min and then separated on a 4% non-denaturing
polyacrylamide gel in 0.5 × TBE (Tris-Borate-EDTA) at 120V for 3 hr. The gel was
dried and subjected to autoradiography. The non-hydrolyzable ATP analogue, adenylyl
imidodiphosphate (AMP-PNP) was obtained from Sigma (St. Louis, MO, USA, Cat#
A2647).

6.14: Unwinding Assay
The probe was generated by annealing two oligos (80ng each) spanning the
central portion of the MCPyV Ori sequence (Figure 2.7 A) (Top Strand Oligo: GTG ACT
TTT TTT TTT CAA GTT GGC AGA GGC TTG GGG CTC CTA GCC TCC GAG GCC
TCT GGA AAA AAA AGA GAG AGG CC; Bottom Strand Oligo: CAG AGG CCT
CTC TCT TTT TTT TCC AGA GGC CTC GGA GGC TAG GAG CCC CAA GCC TCT
GCC AAC TTG AAA AAA AAA AGT CAC). The four-nucleotide overhang was filled
in using Klenow DNA Polymerase (New England Biolabs) by mixing the duplexed probe
in a reaction containing 0.1mM dTTP, dGTP, and [32P-α] dCTP and incubating at room
temperature for 20 min. After adding dATP to a final concentration of 0.1mM, reactions
were incubated for another 20 min at room temperature.

Various amounts of purified MCPyV LT were combined with 60pg of labeled
probe in 20µL unwinding reaction buffer (30mM HEPES [pH 8.0], 0.1mg/mL BSA,
7mM MgCl2, 4mM ATP, 40mM creatine phosphate, 25µg/mL creatine phosphate
kinase). Reactions were carried out at room temperature for 1 hr. Reactions were stopped
	
  

130	
  

by adding 5µL 5×Stop Buffer (2.5% SDS, and 100mM EDTA). Loading dye
(bromophenol blue, 4% sucrose and 1XTBE) was added and samples were separated on
an 11% non-denaturing PAGE in 0.5XTBE. Gels were dried and analyzed using
autoradiography.

6.15: Helicase Assay
The helicase assay was performed as previously described with minor
modification (14). Wild-type or mutant MCPyV LT fused to an IIT tag was expressed in
HEK 293 cells and purified using IgG Sepharose 6 Fast Flow beads (GE Healthcare),
which were preblocked with 1% BSA in PBS at 4 °C for >1 hr. Beads with bound LT
were split into two equal fractions for SDS-PAGE/Coomassie brilliant blue staining and
helicase assays, respectively. To label the helicase assay substrate, 35ng of a 31-mer
oligo (5'-CCA GGG TTT TCC CAG TCA CGA CGT TGT AAA C-3') was annealed to
1µg of M13mp18 DNA (New England BioLabs). The primer was then elongated using
Klenow polymerase (New England BioLabs) in a 50µL reaction containing 0.1mM
dCTP, dGTP, and [α-32P] dATP. After 20 min of incubation at room temperature, 0.1mM
dATP was added and the reaction incubated for another 20 min. Then, 0.5µL of labeled
substrate was used in each reaction. LT purified on IgG Sepharose was incubated with
the substrate in helicase assay buffer (20mM Tris-HCl [pH 7.5], 10mM MgCl2, 1mM
DTT, 0.1mg/mL BSA, and 5mM ATP) at 37°C for 30 min. The reaction was stopped by
adding SDS to a final concentration of 0.2% and EDTA to 50mM. Total reaction
mixtures were resolved by electrophoresis on 11% non-denaturing polyacrylamide gels.
The gels were dried and subjected to autoradiography.
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6.16: Calf-intestinal Alkaline Phosphatase (CIP) Assay
Forty-eight hours post transfection, cells were lysed in lysis buffer (50mM TrisHCl, pH 8.0, 150mM NaCl, 10% Glycerol, 1% NP-40, 5mM MgCl2, 1mM DTT, and
protease inhibitors) and passed through a 26-gauge needle 5 times. Lysates were
incubated on ice for 20 min with occasional vortexing. Lysates were then spun down at
5,000rpm for 5 min at 4˚C. Cleared supernatants were collected. A Bradford assay was
performed to determine protein concentration and lysates were then diluted to 1mg/ml
with lysis buffer. A 100µg aliquot of lysate was used for CIP treatment: NEB buffer 3
was added to the lysate to a final concentration of 1X Buffer, and the solution was
incubated at 37˚C for 5 min. The samples were then treated with 50 units of CIP for 30
min at 37˚C. Samples were boiled in sample buffer and immunoblotted.

6.17: Annexin V Staining
C33A cells were transfected with pEGFPC1, pEGFPC1-MCPyV LT, or
pEGFPC1-MCPyV LT S816A. 24 hours post transfection, cells were washed with
binding buffer (10mM HEPES [pH 7.4], 140mM NaCl, 2.5mM CaCl2), stained with
Annexin V-PE for 10 min, washed once more with binding buffer, and fixed with 3%
paraformaldehyde for 20 min. Nuclei were counterstained with DAPI.

6.18: Retrovirus Production and Stable Cell Line Construction
293T cells were cultured in 10 cm dishes to reach 95%-100% confluency.
pLPCX-based plasmids (pLPCX-Cherry-LacI, pLPCX-MCPyV LT 1-817, and pLPCXMCPyV LT 1-817 S816A), pVSVG, and pMD-gagpol were co-transfected into 293T
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using Lipofectamine 2000 transfection reagent. After 48 hours, the packaged retroviruses
in the supernatant were harvested and filtered through a 0.45µm filter before transducing
C33A and HeLa cells. At 48 hours post-infection, the transduced cells were selected
using 0.625 µg/ml or 1 µg/ml puromycin, respectively, for 4 days. Expression of MCPyV
LT was confirmed by immunofluorescent staining and western blotting, and the selected
cells were maintained as stable cell lines in DMEM supplemented with puromycin.

6.19: In Vitro phosphorylation Assay
To activate ATM and ATR, U2OS cells were treated for 4 hr with 4µM etoposide,
which induces double-strand DNA breaks. Treated cells were harvested and re-suspended
in buffer A [10mM HEPES [pH 7.9,] 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM
DTT, 0.2mM PMSF, 3mM sodium butyrate, 1mM NaF, and 100µM Na3VO4,
supplemented with protease inhibitor cocktails (Roche) and S/T protein phosphatase
inhibitor cocktails (Sigma)], and incubated on ice for 10 min. NP-40 was added to a final
concentration of 0.02% and cells were vortexed for 10 seconds. Nuclei were separated by
centrifugation at 4,000rpm, 10 min, 4°C. Isolated nuclei were lysed in buffer B [20mM
HEPES [pH 7.9], 0.5M NaCl, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.2mM PMSF,
3mM sodium butyrate, 1mM NaF, and 100µM Na3VO4, supplemented with protease
inhibitor cocktails (Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)] by
passing through a 22-gauge needle 10 times, followed by rotation at 4°C for 1 hour.
Nuclear extracts were isolated by centrifugation at 14,000rpm, 10 min, 4°C.
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Nuclear extracts (500µg) were mixed with 10µg rabbit anti-ATM, 10µg mouse
anti-ATR, or 10µg normal rabbit IgG together with 10µg normal mouse IgG. Nuclear
extracts and antibody mixture was rotated at 4°C for 2 hours, and then 10µl protein G
agarose beads (Invitrogen) were added. Mixtures were rotated for another hour at 4°C.
Proteins bound to the resin were washed four times with KCl buffer (20mM Tris [pH
8.0], 10% Glycerol, 5mM MgCl2, 0.1% Tween-20, 150mM KCl, 0.1mM PMSF, 3mM
sodium butyrate, 1mM NaF, and 100 µM Na3VO4, supplemented with protease inhibitor
cocktails (Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)). Resin was
then equilibrated once with kinase buffer (20mM HEPES [pH 7.6], 50mM NaCl, 10mM
MgCl2, 1mM DTT, 20mM MnCl2 and 1mM NaF). IIT-MCPyV LT was purified as
previously described (14) and treated with CIP as described in Section 6.16. MCPyV LT
was cleaved by AcTEV protease (Invitrogen) following the manufacturer’s instructions.

Equilibrated resin (10µL) with purified ATM or ATR proteins was mixed with
30µl kinase buffer, 1µg purified MCPyV LT, 200µM ATP, and 0.5µl of 3,000Ci/mmol
[γ-32P] ATP. Kinase assay was performed at room temperature or 37˚C for 30 min.
Proteins were separated by SDS-PAGE, and the gel was subsequently dried at 80°C for
30 min. Autoradiography was performed as previously described (50).

6.20: Glutathione S-Transferase Pull-Down Assay
BL21(DE3)pLysS E. coli were transformed with pGEX-MCPyV LT or pGEX
vector. Bacteria were lysed with lysis buffer (10mM Tris-HCl [pH 8.0], 50mM NaCl,
0.4mg/ml lysozyme, 2mM DTT, 0.1mM EDTA, supplemented with protease inhibitors)
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before running through Q-sepharose (Sigma) and SP-sepharose (Sigma) columns. The
SP-sepharose column was washed with buffer (50mM Tris-HCl [pH 8.0], 150mM NaCl,
2mM DTT, 0.1mM EDTA, supplemented with protease inhibitors) before elution with
the same buffer containing 400mM NaCl. Elution was then incubated with GSH-agaorse
(Sigma) at 4°C for 2 hr. GSH-agarose was washed five times with wash buffer (20mM
Tris-HCl [pH 8.0], 5mM MgCl2, 0.1% Tween-20, 100mM KCl, supplemented with
protease inhibitors). Bound proteins were used for GST pull-down assay. Briefly, U2OS
nuclear extracts was prepared as previously described (156) and incubated with beads
bound with GST or GST-LT at 4°C overnight. The beads were washed three times with
0.5ml of 0.1 M KCl buffer and eluted with 30ul of SDS-PAGE sample buffer.

6.21: Clonogenic Assay
C33A cells stably expressing Cherry-LacI, LT 1-817 or LT 1-817 S816A were
plated in triplicate at 5 X 103 cells/well in a 6-well plate, and cultured in DMEM medium
with 10% FBS and 0.625µg/ml puromycin for 10 days. The cells were then fixed with
methanol and stained with 0.5% methylene blue.

6.22: Luciferase Assay
293 cells were plated in triplicate at 2 X 103 cells/well in a 6-well plate and
cultured in DMEM with 10% FBS. Cells were co-transfected with the luciferase reporter
plasmid and viral protein expression constructs indicated in the figure legends using the
calcium phosphate method (50). Cells were collected at the indicated time points using
the Reporter Lysis system (Promega) following the manufacturer’s instructions. Protein
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concentration was measured by NanoDrop. Luciferase activity was measured using the
Luciferaase Assay System (Promega) according to the manufacturer’s instructions and
normalized to protein concentration.

For ISRE activation in Figure 4.2, cells were

stimulated 24 hrs post transfection with 1,000units/per well recombinant IFN-α, and
collected 48 hrs post transfection.

6.23: Statistical Analyses
Prism software was used to perform a one-way ANOVA test. A p < 0.05 was
considered statistically significant.
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